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A STUDY OF POLYSOMNOGRAPHY AND SERUM GHRELIN 
LEVELS IN PATIENTS WITH GENERALIZED TONIC CLONIC 
SEIZURES: 
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BACKGROUND: 
          There is a complex relationship between sleep and epilepsy. They are 
reciprocal to each other.  
 
METHOD: 
          A total of 30 generalized tonic clonic seizure patients and 30 controls 
were subjected to polysomnography. It simultaneously records the three 
physiological measures that define the stages of muscle tone, recorded through 
Electromyogram (EMG), eye movements, recorded through the Electro-
oculogram (EOG) and brain activity, recorded through the 
Electroencephalogram (EEG), and compared with equal number of  normal 
individuals. Ghrelin is peptide hormone, secreted from stomach. Its level was 
measured in the fasting state. Its level increased before food intake and 
decreased after food intake. 
RESULTS: 
      The mean age of the study groups were comparable 31.10±5.6 for GTCS 
patients and 30.03±6.26 for control groups as well as body mass index for 
GTCS patients (26.89±0.99) and for control groups (26.30±1.46). In this study, 
sleep architectural changes, mainly prolonged stage I (18.35±2.85 for GTCS 
and 14.6±2.6 f0r control group)and stage II of NREM sleep and reduced REM 
sleep(63.93±13.21 for GTCS and 77.27±13.3 for control group) occurs in 
GTCS patients than comparative with control group leads to fragmentation of 
sleep. And also serum ghrelin levels were decreased  in these patients.  
 
 CONCLUSION: 
                   Sleep disturbances are more common in the epileptic patients. It will 
further worsening the seizure propensity. Identifying and treating these 
associated sleep problems, also an important part in the management of 
epilepsy.  
Keywords:  ghrelin, generalized tonic clonic seizures, polysomnography. 
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A STUDY OF POLYSOMNOGRAPHY AND SERUM 
GHRELIN LEVELS IN PATIENTS WITH 
GENERALIZED TONIC CLONIC SEIZURES 
INTRODUCTION: 
Epilepsy is a chronic disorder characterized by a spontaneous 
tendency for recurrent seizures. Seizures are the clinical 
manifestation of abnormally hyper excitable cortical neurons. 
The clinical manifestations of the attack may vary from 
complex abnormalities of behaviour including generalized or focal 
convulsions to momentary spells of impaired consciousness. 
Based on the type of behaviour and brain activity, seizures 
are classified into two categories generalized and partial. 
Generalized seizures are produced by electrical impulses arise from 
overall brain. Partial seizures are produced by electrical impulses 
arise from a small area of brain. 
The most common type is generalized tonic - clonic seizures 
or grandmal seizures. 
The terms seizure, convulsion, or epilepsy are often 
associated with generalized tonic clonic seizures. 
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Generalized tonic- clonic seizures may occur in any age. 
They can occur as a single episode or as a part of a repeated, 
chronic illness. 
Symptoms of Generalized tonic - clonic seizures: 
Many persons with these seizures have vision, taste, smell, or 
sensory changes, hallucinations, or dizziness before the seizure. 
This is called an aura. 
The seizures usually result in rigid muscles. This is followed 
by violent muscle contractions and loss of consciousness. Other 
symptoms are biting of the tongue, clenched teeth, loss of urine or 
stool control, difficulty in breathing, blue skin colour. 
After the seizure, the person may have confusion, sleepiness 
that lasts for 1 hour, loss of memory, headache. 
Risk factors for generalized tonic- clonic seizures: 
A family history of seizure disorder, any injury to the brain 
from trauma, stroke, previous infection and other causes, sleep 
deprivation, electrolyte imbalance, drug abuse, heavy alcohol use. 
The incidence of sudden death is 24 times higher in patients 
with epilepsy than in general population. 
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Risk factors for sudden death in epilepsy (SUDEP) include 
high seizure frequency, younger age, mental retardation and poly 
therapy.  
Sleep disturbance is common in epilepsy. The nature of sleep 
disturbances in epilepsy is diverse, and the aetiologies are complex. 
Patients with epilepsy commonly produce complaints of 
daytime sleepiness and poor quality of sleep. These problems are 
frequently attributed to antiepileptic drugs and seizures. 
NORMAL HYPNOGRAM: 
 
During sleep, we mostly pass through five stages 1,2,3,4, and 
REM (Rapid eye movement) sleep. These stages progress in a 
sequence from stage 1 to REM sleep, then the cycle repeats from 
stage 1. Among  these almost 50 percent of our total sleep time is 
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occupied by stage 2 sleep, about 20 percent by REM sleep ,and the 
remaining 30 percent in the other stages. Infants, on the other side, 
run through about half of their sleep time in REM sleep. 
HYPNOGRAM ACCORDING TO THE AGE: 
 
Hours of sleep against age 
Children need more sleep per day in order to develop and 
function properly: up to 18 hours for newborn babies, with a 
declining rate as a child ages. REM sleep of a newborn is nearly 9 
hours a day. After the age of five REM sleep component declines 
nearly more than two hours. 10 to 11 hours of sleep is required for 
school children as evidenced by studies1. 
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AGE AND CONDITION SLEEP NEEDS 
Newborns (0–2 months)  -  12 to 18 hours 
Infants (3–11 months)  -  14 to 15 hours 
Toddlers (1–3 years) -  12 to 14 hours 
Preschoolers (3–5 years)  -  11 to 13 hours 
School-age children (5–10 years)  - 10 to 11 hours 
Adolescents (10–17 years)  - 8.5 to 9.25 hours 
Adults, including elderly -  7 to 9 hours. 
1.1 PHYSIOLOGY OF SLEEP: 
This is widely divided into two following Phases of Sleep 
according to the multiple electrophysiological recording parameters 
as Rapid Eye Movement (REM) and Non-Rapid Eye Movement 
(NREM). 
1.2 STAGES OF SLEEP CYCLES: 
The EEG pattern recorded during sleep varies in a cyclic 
fashion, which repeats in about every 90 minutes. There are about 
four cycles in normal 6 to 8 hours of sleep. In normal individuals, 
sleep cycle begins with slow-wave sleep or Non-REM sleep. There 
are four stages of slow wave sleep: stages 1 to 4. 
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A person when falls asleep, passes sequentially through these 
four Stages of increasingly deep sleep. After that, the sleep lightens 
and he enters into REM period. With completion of REM phase, 
sleep cycle completes. The REM phase is followed by the next new 
cycle, i.e. with stage 1 of non-REM sleep. 
Thus, the cycle repeats in every 70 to 90 minutes. Throughout the 
night, people wake up briefly (called stage W) but are typically unaware 
of being awake. There are differences in the proportion of time spent in 
the various sleep stages in different age groups. Moreover, each 
individual has his or her own characteristic pattern. Usually, there is a 
predominance of deep slow wave sleep during the early part of the 
night, and the first REM sleep may occur after an hour. 
REM stage becomes prevalent during the later part of the 
night. In general, REM sleep occupies about 25 per cent of total 
sleep period. The duration of REM sleep and stage 4 sleep decrease 
gradually with advancing age. Newborns and infants sleep about 18 
hours a day of which 50% is spent in REM sleep. 
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1.3 EEG FEATURES OF SLEEP 
In 1953, Aserinsky, Dement and Kleitman through EEG and 
polygraphic analysis described different phases of normal sleep 
characterized by EEG, autonomic and endocrine changes. 
During wakefulness, EEG usually shows desynchronized, 
highfrequency, low amplitude known as beta waves in the range of 
14 – 30 Hz. During quiet rest with eyes closed, waves range from 8 
to 12 Hz, i.e. alpha waves. 
1.4 ARCHITECTURE 
Non-REM sleep: 
Stage 1 : Alpha rhythm is replaced by high frequency 
low amplitude EEG waves. 
Stage 2 :  Appearance of sleep spindles and K complexes. 
Stage 3 & 4 :  Delta waves (slow wave) 
(Commonly called as deep sleep)- Delta waves in EEG reflect 
synchronized oscillations of thalamocortical circuit activity. 
REM sleep: 
High frequency, low amplitude activity with PGO spikes. 
REM is characterized by rapid eye ball movement and profound 
atonia of other limb muscles (except for extraocular, inner ear and 
respiratory muscles). 
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Among these stage 2 sleep occupies50 percent of our total 
sleep time, REM sleep 20%, and the remaining 30 percent in the 
other stages. 
Infants sleep on the other hand, occupies 50% of their sleep 
time in REM sleep. Recent evidences show that “theta oscillations 
during REM are driven by neurons in the proceruleus area in pons and 
atonia is caused neurons in the adjacent sublaterodorsal area. (Lu et 
al, 2006).These ‘REM on’ zones are inhibited by nearby ‘REM off’ 
area including ventrolateral PAG and lateral pontine tegmentum. 
‘REM on’ area can also inhibit ‘REM off’ area. Mutual inhibitions 
between these areas produce ‘flip-flop switch’ that ensures sharp and 
complete transition between REM and NREM sleep”. 
REM switch is influenced by: 
• Cholinergic neurons that promote REM sleep 
• Noradrenergic and serotonergic neurons that inhibit REM sleep. 
NREM Sleep-changes in EEG and consciousness (which is 
primarily a cerebral function) are classified into four stages 
respective to increasing depth of consciousness. Depth of 
unconsciousness will become more for as sleep progresses from 
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stage 1 to 4. EEG shows a progressively slower in frequency and 
higher-voltage pattern (furthermore called slow wave, delta wave) 
NREM-Thinking and Body Activities: 
Thinking in NREM is short, rudimentary and not able to 
recollect, Muscle tone is present, and Deep Tendon Reflex can be 
elicited. Chin and limb muscles exhibit EMG activities. 
NREM sleep-autonomic changes: 
Widespread decrease in autonomic activities, hypotension and 
decreased heart rate, and decreased generalized cellular metabolism 
are noted. 
NREM sleep-Hormonal changes: 
Growth Hormone, Cortisol and Prolactin secretion occurs 
mostly in NREM sleep. GH is secreted in 30 to 60 minutes after the 
beginning of sleep. Biochemical changes like increased serotonin 
activity is noted in NREM sleep. 
Function of NREM sleep: 
Main characteristics of NREM sleep are slow wave in EEG, 
decreased generalized metabolic activities and deep unconsciousness 
help revitalize the body. Hence, early night time period is occupied 
by NREM or slow wave sleep predominantly, while late night phase 
is occupied by REM which is lighter and dream filled. 
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EEG/EMG characteristics of REM sleep: 
EEG is more active than NREM. Low voltage fast with ocular 
movement artifact is noted in EEG. EMG is relatively reflecting 
atonia in REM sleep related to flaccid muscles. While other body 
activities are as active as like that of awake state. 
Latencies: 
“Sleep latency is defined as the interval to fall asleep after 
retiring. Normal range is 10-20 minutes”. 
The occurrence of seizures can have profound effects on sleep 
architecture lasting longer than the post ictal period. Significant 
sleep interruption in epilepsy has been associated with impaired 
seizure control. All the aspects of sleep should be evaluated, and 
sleep disturbances should be treated as part of the total care of 
patients with epilepsy. 
In epilepsy patients, formal sleep evaluation demonstrates 
significantly reduced REM and stage 4. Patients having nocturnal seizures 
show reduced sleep efficiency, increased time to first REM period. 
Seizures can also influence changes in sleep. They demonstrates  
multiple sleep abnormalities, including increased sleep latency, fragmented 
sleep, increased awakenings and stage shifts, and an increase in stages 1 and 
 11 
2 of  non-rapid eye movement sleep (Foldvary -Schaefer and Grigg – 
Damberger  2009)1 
Physiologic changes involved in the non rapid eye movement 
(NREM) sleep are associated with increased susceptibility to seizures. 
Ghrelin is a 28 aminoacid peptide hormone that is secreted 
mainly by stomach cells with small amounts secreted by other cells 
(hypothalamus), that is a growth hormone secretagogue, and that has 
been implicated in the, stimulation of fat storage and food intake. 
Ghrelin is a hormone with multiple functions( korbonits et al 
2004)71. It has been reported to affect cardiac and gastrointestinal 
function, carbohydrate metabolism, adipose and reproductive 
tissue, cell proliferation and behaviour as well as affecting sleep 
and pituitary hormone axis function. 
Ghrelin promotes slow-wave sleep in humans (Weikel, J.C et al) 
2
   Short sleep duration is associated with high levels of ghrelin and 
obesity. An inverse relationship between the hours of sleep and 
blood plasma concentrations of ghrelin exists: as the hours of sleep 
increase, ghrelin levels lower and obesity is less likely. 
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REVIEW OF LITERATURE 
HISTORY OF EPILEPSY: 
Epilepsy is an enigmatic disorder which had different outlook 
and approach in different era. 
The term Epilepsy originated from the Greek word “seize” or 
attack and probably was derived from the idea of the individual 
being seized or attacked by Gods (Temkin O et al 1971)3. 
In fifth –century B.C, Hippocrates, the father of medicine 
made several observations regarding Epilepsy, which was then 
referred to as the “Sacred disease (Eadie MJ et al 2001)4. He 
attributed the cause of Epilepsy to a physical condition, specifically 
a hereditary excess of phlegm in the brain. At that time epilepsy 
was attributed to a variety of causes, including smiting by the Gods, 
demonic possession, prophetic trances, insanity etc. 
Another Greek physician, Galen used the term “aura” to 
describe the feeling ‘like a cold breeze’ that travelled up the body 
from the log prior to a seizure. 
In the Christian era in Europe ,epilepsy was no longer 
considered the “Sacred disease”, but thought to be due to evil 
possession .In the seventeenth century ,two famous anatomists, 
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Franciscus sylvius and Thomas Willis carefully studied the brain 
and developed theories to explain the epileptic phenomenon. 
However, the outlook changed with the dawn of scientific 
medicine in the 19th century when Sir Charles Locock in England, 
observed that the administration of bromides seemed to cure 
epilepsy in young adult women. Following this phenobarbitone and 
phenytoin evolved as highly effective anticonvulsants. In the 1940 s 
and 1950 s, there was a flurry of drug discoveries. Since 1990, a 
variety of pharmacologic, non pharmacologic and surgical 
approaches to treatment have been introduced. 
With improved treatment available for epilepsy, diagnosis 
became an increasingly important issue and the recording of abnormal 
brain electrical activity became mandatory. In 1924, Hans Berger 
from university of Jena psychiatric clinic of Otto (Berger H, et al 
1969) 5 made the breakthrough of first scalp recording of normal brain 
electrical activity and called the recording an “Elektenkephalogram”. 
From 1950 s, neuroscience research involving epilepsy 
quickened, leading to remarkable discoveries about genetics, 
pathology, physiology, diagnostic tools and treatment of epilepsy. 
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EPIDEMIOLOGY: 
Next to stroke and Alzheimer’s disease, Epilepsy is the third 
most common neurologic disorder. 
Approximately 2 million (0.5-1.5% of population) peoples 
suffered from this disorder in the United States. Each year 50 per 1, 
00,000 persons in the United States will be diagnosed with 
epilepsy, frequency of seizures more in   of new cases occurring 
among the children<5 years and adults>65 years of age. 
Epilepsy is one of the most common and serious neurological 
disorders affecting 65 million people globally (Thumaran et al) 6. 
It affects 1% of the population by age 20 and 3% of the population 
by age 75(Holmes et al) .Most of those with disease nearly 80% are 
in the developing world (Newton CR et al) . It is more common in 
males than females. 
5-10 per 1000 peoples are having active epilepsy now. It 
means patient had at least one seizure in the last 5 years. Poverty is 
one of the important risk factor for epilepsy. In the developed 
world, either it starts in the young or in the old. But in the 
developing world its onset is more common in older children or 
young adults due to higher rates of trauma and infectious disease i. 
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Epilepsy begins each year in 80-140 per 100,000 persons in 
developing countries and in developed countries 40-70 per 10,000 
persons (Sander JW et al 2003). 
Approximately 181,000 new cases of epilepsy and seizures 
occur each year.  About 2.3 million Americans have epilepsy. Half 
of the people with epilepsy develop seizures by the age of 25; 
however anyone can get epilepsy at anytime. 
Between 1.5% and 5% of Americans have seizure at some 
occasion in their lives and about 0.5% have epilepsy, according to 
the National Institutes of Health. 
Aetiology of Seizures and Epilepsy: 
Seizures occur as result of a shift in the normal balance of 
inhibition and excitation within the central nervous system (CNS). 
The normal human brain has a tendency to develop seizures under 
certain circumstances, and there are differences between 
individuals in the susceptibility for seizures. There are various 
endogenous factors involved in the seizure occurrence. Normal 
brain development also plays important role, since the brain 
appears to have different seizure thresholds at various maturational 
stages. There are certain conditions that have a high possibility of 
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developing a chronic seizure disorder. Seizures are episodic. 
Patients with epilepsy have seizures intermittently and, depending 
on the underlying reason, many of them are completely normal for 
few months to years between seizures. Certain precipitating factors 
are responsible for causing the single seizure in some persons 
without epilepsy. This implies a dynamic interplay between 
endogenous factors, epileptogenic factors, and precipitating factors.  
CAUSES OF SEIZURES ACCORDING TO AGE: 
Neonates (<1 month): 
• Perinatal hypoxia and Ischemia 
• Acute CNS infection 
• Intracranial haemorrhage and trauma 
• Metabolic impairments (hypo glycaemia, hypocalcaemia, hypo 
magnesemia, vitamin B6 deficiency) 
• Genetic causes 
Infants and children (>1 month and < 12 years): 
• Febrile seizures Genetic disorders (metabolic, degenerative, 
primary epilepsy syndromes) 
• CNS infection 
• Developmental disorders 
• Idiopathic 
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Adolescents (12-18 years): 
• Trauma 
• Infection 
• Brain tumour 
• Genetic disorders 
• Idiopathic 
Young adults (18-35 years): 
• Trauma 
• Alcohol withdrawal 
• Illicit drug use 
• Idiopathic 
Older adults (>35 years): 
• Cerebrovascular disease 
• Brain tumour 
• Metabolic disorders (uraemia, hepatic failure, electrolyte 
abnormalities, hypoglycaemia, and hyperglycaemia) 
• Alcohol withdrawal 
• Alzheimer’s disease and other degenerative CNS diseases 
• Idiopathic 
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The most common variety of seizures arising in late infancy 
and early childhood are febrile seizures, which are seizures 
associated with fever but not associated with any evidence of CNS 
infection. The overall prevalence is 3-5% and even high in some 
parts of world. Patients often have a history of epilepsy in their 
family. Febrile seizures usually occur between 3 months and 5 
years of age and peak between 18 and 24 months. The seizures 
usually occur during the rising phase of fever that is the first day of 
fever rather than the further days. 
Febrile seizures divided into two types. First type is simple 
febrile seizure is a single, isolated event, symmetric and brief in its 
course. Second type is complex febrile seizures manifests as 
repeated seizure activity, lasts more than 15 minutes. 
Approximately < 10% peoples have three or more episodes and one 
third of patients will have a recurrence. Recurrences are more if the 
febrile seizures occur in the first year itself. Complex febrile 
seizures have a tendency to develop into epilepsy approximately 2-
5% of peoples.   
 19 
TYPES OF EPILEPTIC SEIZURES: 
 
International classification of epileptic seizures: 
This classification is proposed by International League 
against Epilepsy (ILAE) and based on the clinical expression and 
electroencephalographic features of seizures during and between 
the episodes, approved in September 1981. It is mainly divided into 
partial and generalized seizures. 
Partial seizures (seizures beginning locally): 
a. Simple partial seizures (consciousness not impaired) 
1. With motor symptoms 
2. With somato sensory or special sensory symptoms 
3. With autonomic symptoms 
4.  With psychic symptoms 
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b. Complex partial seizures (with impairment of consciousness) 
1. Beginning as simple partial seizures and progressing to 
impairment of consciousness. 
a) With no other features 
b) With features as in A1-4 
c) With automatisms 
With impairment of consciousness at onset 
a) with no other features 
b) with features as in A1-4 
c) with automatisms 
C. Partial seizures secondarily generalized 
II. GENERALIZED SEIZURES (bilaterally symmetrical and 
without local onset) 
A. 1. Absence seizures 
2. Atypical absence seizures 
B. Myoclonic seizures 
C. Clonic seizures 
D. Tonic seizures 
E. Tonic – clonic seizures 
F. Atonic seizures 
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III UNCLASSIFIED EPILEPTIC SEIZURES 
In partial seizures the abnormal electrical impulses start in a 
localized area of the brain. Based on the part involved in the brain, 
clinical manifestations are expressed. These impulses may remain 
localized or they may spread to other areas of brain and then the 
seizure becomes generalized called secondarily generalized 
seizures. 
On the other hand, generalized seizures are starts from both 
the hemispheres simultaneously, generalized in onset. 
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During lifetime, one patient may have a combination of 
seizure types, not necessarily have only one type of seizure. 
Depending on the age and maturation of the brain, the type may 
change. A definite aura is an indication of seizure of focal onset. 
pathophysiological processes leading to epilepsy: 
 
                                              Epileptic discharges 
 
 This picture shows that seizure generation results from 
increased excitation and decreased inhibition, or both. 
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Mechanisms of Seizure Initiation and Propagation (Harrisons text 
book of internal medicine) 7: 
There are two phases in the seizure occurrence. First seizure 
initiation phase characterized by two concurrent events in an 
aggregate of neurons. 
1. High- frequency bursts of action potentials 
2. Hyper synchronization 
The bursting activity is due to long-lasting depolarization of 
the neuronal membrane due to influx of extracellular calcium 
(Ca2+), which leads to the opening of sodium channels (Na+), 
influx of Na+, and generation of repetitive action potentials. This is 
followed by a hyperpolarizing after potential mediated by gamma 
amino butyric (GABA) receptors or potassium channels, depending 
on the cell type. The synchronized bursts from a number of neurons 
result in a so-called spike discharge on the EEG. 
This spread of activity normally prevented by intact 
hyperpolarization and inhibition produced by surrounding 
inhibitory neurons. With adequate activation there is a recruitment 
of surrounding neurons via a number of synaptic and non synaptic 
mechanisms, including: 
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1. Excessive extracellular k+, which blunts hyper polarization and 
depolarizes neighbouring neurons.  
2. Calcium ions accumulated in the pre synaptic terminals, leading 
to increased neurotransmitter release 
3. Depolarization-induced activation of the (NMDA receptors) N-
methyl-D- aspartate subtype of the excitatory amino acid receptor, 
which causes additional Ca2+ influx and neuronal activation 
4. Ephaptic interactions related to changes in tissue osmolarity and 
cell swelling. 
The recruitment of a sufficient number of neurons leads to the 
propagation of seizure activity into contiguous areas through 
cortical connections and to more distant areas via long commissural 
pathways. There are many mechanisms for altering a neurons 
propensity to have bursting activity and many factors control the 
neuronal excitability. 
There are two types of mechanisms. 
First one is the intrinsic mechanisms; include changes in the 
conductance of ion channels, cytoplasmic buffering, second- 
messanger systems, and protein expression as determined by gene 
transcription, translation, and posttranslational modification. 
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Second extrinsic mechanisms are changes in the amount or type of 
neurotransmitters present at the synaptic level, modulation of 
receptors by extracellular ions, and temporal and spatial properties 
of synaptic and non synaptic input. Astrocytes and 
oligodendrocytes, have an important role in many of these 
mechanisms.  
Mechanisms of Epileptogenesis: 
Epileptogenesis refers to the transformation of a normal 
neuronal network in to one that is chronically hyper excitable. 
There is often a delay of months to years between an initial injury 
and the first seizure. The injury appears to initiate a process that 
gradually decreases the seizure threshold in the affected region 
until a spontaneous seizure occurs. In many idiopathic and genetic 
forms of epilepsy, epileptogenesis is determined by 
developmentally regulated events. 
GENETIC CAUSES OF EPILEPSY: 
Identification of Genetic mutations associated with epilepsy 
syndromes are the most important recent research progress in 
epilepsy. Most of the inherited, idiopathic epilepsies due to 
mutations affecting ion channel function. 
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Identification of multiple susceptibility genes that underlie 
the common forms of epilepsy is the current challenge of epilepsy 
research. Recent studies suggest that chromosomal micro deletions 
and ion channel mutations may be the cause of epilepsy. 
TONIC- CLONIC SEIZURES: 
   These seizures are also called grandmal seizures. It is the 
most typical type seen in adults. More than half of the patients with 
epilepsy may experience a generalized tonic – clonic seizures in the 
course of the disease process.  
EEG FEATURE OF GTCS: 
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Prior to the attack, some patients may experience vague 
symptoms called an ‘aura’. This may be a taste or a smell, or just 
‘feeling strange’. It may last for a few seconds, which may be 
enough for the patient to be able to lie down, thus preventing injury 
due to falling during seizure attack. However most of the patients 
do not have any warning symptoms. 
The typical seizure of this type has three phases.  
The first phase is the tonic phase, which last for about 10 to 
40 seconds. The patient become vey rigid, as all the muscles in the 
body undergo tonic sustained contractions. The patient falls rigidly 
and as the laryngeal and respiratory muscles are also contracted, 
may let out a cry or grunt as air is forced out of the chest through 
the vocal chords. During this time the patient becomes cyanotic due 
to insufficient respiration. 
This is followed by the second phase called clonic phase, 
during which the muscles go in to strong random contractions. This 
limb jerking may be accompanied by faecal and urinary incontinence, 
and there may be tongue and biting and frothing at the mouth. 
Breathing is inefficient and jerky and there is tachycardia. This phase 
last for 2 to 3 minutes, although it may extends longer. 
 29 
The third phase is a coma, in which the patient breathing 
becomes irregular. Their colour becomes normal. The length of this 
phase is related to   the duration of previous tonic clonic phases, 
while recovery the patient may appears to be confused and have a 
headache. During that seizure attack there will be reduction of 
respiration leads to poor oxygenation of the blood. There is an 
accumulation of lactic acid in brain. The probable cause of the 
coma is hypoxia and acidosis. 
Blood investigation shows increased pH, decreased pO2,  
increased creatinine phosphokinase and serum prolactin levels.  
  
  
Repeated seizure attacks can lead to neuronal degeneration 
which is due to the excessive synthesis of glutamate. This can cause 
cell death due to excitotoxicity. 
SUDEP: (sudden unexpected death in Epilepsy) 
Sudep is the non accidental death in patients with epilepsy. 
on autopsy, cause of death is unknown. 
The rate of SUDEP is approximately 1 death in 1000 people 
with epilepsy per year. It is the leading cause of death in people 
with uncontrolled epilepsy. Its cause is multifactorial. The main 
risk factor for sudep is frequent seizures, especially in grandma 
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seizures (generalized tonic-clonic seizures). Other risk factors are 
long duration and early onset of epilepsy, fails to take antiepileptic 
medications, young age (20-40), IQ< 70. Some studies explain 
higher risk of SUDEP seen in patients taking multidrug therapy. 
GHRELIN HORMONE: 
Introduction: 
(Ghrelin-Growth Hormone Release Inducing) 
The name Ghrelin is derived from Growth Hormone Release 
Inducing hormone.  This hormone has its role as a growth hormone 
releasing peptide. 
Discovery of Ghrelin hormone: 
It was discovered after the discovery of its receptor (Ghrelin 
receptor-Growth hormone secretagogue receptor (GHSR) by 
Howard et al8. It was discovered in 1996, reported later in 1999 
and its natural ligand was not known. Three years later (1999), its 
natural ligand, Ghrelin identified by Kojima et al9 from the rat 
stomach. 
Ghrelin is the most potent circulating orexigen, and its 
plasma levels are elevated prior to the meals and it stimulates 
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feeding (Wren et al 2001)85. So, ghrelin is also called hunger 
hormone .Ghrelin is encoded by the GHRL gene. 
Figure          Aminoacid Sequence of Ghrelin 
 
Figure GHRELIN AND PREPROGHRELIN                                                                     
 
Green and blue-Pre pro ghrelin, Green-Ghrelin 
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Figure               Formation of Ghrelin from prepro-Ghrelin.  
                   Types of Ghrelin acylated and unacylated Ghrelin.   
  
 
The ghrelin gene contains preproghrelin - coding exons 
(exons1-4). During processing, a 23 amino acid secretion- signal 
peptide is cleaved from the 117 amino acid preprohormone (N-
terminus), resulting in 94 amino acid proghrelin . This peptide 
further cleaved and gives rise to 28 amino acid ghrelin peptide and a 
66 amino acid C-terminal propeptide, C-ghrelin (Pemberton et al 
2003). Following the cleavage from proghrelin, the ghrelin peptide 
can be posttranslationally octanoylated at its third residue serine, by 
enzyme ghrelin O-acyl transferase(GOAT)(Gutierrez et al 
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2008)10.  This modified form is referred to as ghrelin. A non-
octanoylated form of ghrelin ( unacylated ghrelin, des-acyl ghrelin, 
des-ghrelin) circulates in the higher level in the blood (Holmes et al., 
2009)84. It does not bind with its receptor (GHSR 1a), as previously 
considered as biologically inactive.  
GOAT: 
GOAT, enzyme responsible for octanoylation of ghrelin is a 
member from the membrane- bound O-acyl transferase (MBOAT) 
family of enzymes, encoded by the MBOAT4 gene. It is a 
hydrophobic, membrane-bound enzyme with 8 domains, localised 
to the endoplasmic reticulum (Yang et al 2008a)11. It is co 
expressed with ghrelin in the cells of stomach and in the pancreatic 
islets and other sites including chondrocytes (Gomez et al 2009)88. 
This enzyme is an attractive and specific target for the modification 
of octanoylation (Yang et al., 2008b)11, also it could provide a 
target for development of drugs to prevent weight gain, obesity, 
insulin resistance (Barnett et al 2010)89. It also plays an important 
role in the regulation of metabolism and lipid - sensing, in the gut 
and links between energy intake with endocrine balance (Kirchner 
et al 2009)87.             
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This c-ghrelin (has 66 amino acids) cleaved to give obestatin  
Relation between ghrelin and obestatin: 
Obestatin , which is C- terminally amidated and also it has 
opposite effects to ghrelin hormone on food intake( Zhang et al., 
2005). It has multiple roles including, adipogenesis, in sleep, 
pancreatic homeostasis and cancer ( Seim et al15.,).  
Figure                  Formation of Obestatin from Ghrelin 
 
When octanoic acid (caprylic acid) is linked to serine 
posttranslationally at the third position by the enzyme ghrelin O-
acyltransferase (GOAT) ,brings ghrelin becomes active. This 
enzyme located on the cell membrane of ghrelin cells in the 
pancreas and stomach ii. 
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Ghrelin is a peptide hormone produced by ghrelin cells in the 
gastrointestinal tract which acts as a neuropeptide in the central 
nervous system. Ghrelin cells are found in oxyntic glands ( 20%), 
pyloric glands, small intestine. They also produce another food 
intake limiting hormone Nesfatin-1(Inhoff T et al12).They also 
present in lungs, pancreatic islets, gonads, adrenal cortex, placenta, 
kidney. They are ovoid cells with granules (Grube D et al,)13. They 
have gastrin receptors. 
Other names of ghrelin cells are A-like cell, X cell, X/A- like cell( 
rat), Epsilon cell( pancreas), P/D sub 1cell(humans)( Zigman JM et al)14. 
Growth Hormone Secretagogue Receptor: 
GHSR 1a is a classical, 7- transmembrane domain, G protein-
coupled receptor.  
The ghrelin hormone secretogogue receptor (GHSR1a) is 
involved in so many functions of ghrelin. It includes stimulation of 
growth hormone release, regulation of motility and secretion of gastro 
intestinal system, increase in hunger, regulation of immune function 
and also has roles in sleep and memory. These receptors are situated 
in high density in the hypothalamus, pituitary, throughout the 
gastrointestinal tract and on the vagus nerve (Seim I et al)15. 
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Another form is GHSR 1b isoform is thought to be inactive 
because it does not bind ghrelin and ghrelin does not activate 
signalling via this receptor ( Feighner et al., 1998)86. It is over 
expressed in lung cancer. Although its function is not clear, it act as 
a negative regulator of GHSR 1a by reducing its cell surface 
expression and constitutive signalling (Leung et al., 2007)17. Its 
over expression in many cancers indicates, its clinical significance 
(Barzon et al., 2005)90. 
The non-octanoylated form is DESACYL GHRELIN. This 
form does not activate the GHSR receptor, but it has involved in 
other actions such as cardiac function, appetite stimulation, anti 
ghrelin, inhibition of hepatic glucose output. 
GHRELIN AND LEPTIN: 
Ghrelin hormone discovered 7 years after Leptin hormone. 
Leptin is also a hormone involving in appetite regulation. It has 
opposite effect in appetite regulation in relation to ghrelin68. 
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Figure      Relation between Ghrelin and Leptin 
 
 
 
Figure   Ghrelin and Leptin levels in relation to meals: 
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Orexigenic action of ghrelin: 
 
ACTIONS OF GHRELIN HORMONE : 
Role in the nervous system; 
1.Sleep: 
There is an inverse relationship between the plasma 
concentration of ghrelin and hours of sleep. Short sleep duration is 
associated with increased ghrelin levels and obesity. Its levels 
become lower when the hours of sleep increases and the possibility 
of obesity also reduced59. 
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Figure    Functions of Ghrelin 
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2. Learning and memory: 
In the brain hippocampus plays a significant role in the 
learning and the cognitive adaptation to changing environments. 
From the blood stream, ghrelin may enter the hippocampus, altering 
the nerve cell connections and also altering memory and learning 
proved in animal models. It is suggested that learning may be best 
when the stomach is empty during day time, because ghrelin 
concentrations are at high level (Diano et al,2006)54 , (Ateha et 
al,2009)55. 
3. Role in prevention of depression:  
Its role in depression is demonstrated by animal 
studies.(Spencer et al,2012)57. 
4. Role in stress: 
Serum ghrelin levels are raised in stress even in the absence 
of adrenal hormones. This is necessary for learning of fear during 
stress situations. (Meyer et al, 2013)60 
5. Role in growth hormone release:  
It has important role in growth hormone release. 
 
 
 41 
ROLE OF GHRELIN IN GROWTH HORMONE RELEASE: 
 
Gastro intestinal tract: 
It promotes the proliferation of intestinal cells and inhibits 
apoptosis during oxidative stress (Wasseem et al 2004)45.46.  
 
 42 
It enhances anti inflammatory mechanisms, thus involved in 
the treatment of inflammatory conditions in gastro intestinal 
system. Also it has regenerative tendency, useful in treatment of 
mucosal injuries in the stomach(Ishres et al)49. 
On pancreas: 
Ghrelin acts via its receptor in the pancreas to inhibit glucose 
induced insulin secretion. 
In glucose metabolism, it has a gluco regulatory 
action(Heppner et al  2014)53 
Role in obesity: 
Its level low in obese persons except in prader-willi syndrome 
associated obesity. (Cumming DE et al 2002)65Lack of sleep 
enhances ghrelin and decreases leptin level leading to obesity 
due to excessive production of hunger. 
In anorexia: 
Ghrelin levels are high in anorexia nervosa and cancer 
induced cachexia patients.(Misra M et al 2014)68 
Role in immune system: 
Ghrelin gene products have actions on auto 
immunity.(Prodam et al )64 
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Role in reproductive system: 
It has inhibitory action on gonadotropin-releasing hormone 
secretion and causes decreased fertility. (Comninos AN et al 
2014)62 
Role in fetus and neonates:  
Ghrelin hormone synthesized by the fetal lung and promotes 
lung growth.(Santos M et al )63 One study shows a correlation 
between ghrelin levels and birth weight by using cord blood 
levels.(Yokota I et al 2005)43 
THERAPEUTIC APPLICATIONS OF GHRELIN: 
1. Growth hormone deficiency 
2. Eating disorders 
3. Anorexia nervosa, Bulimia nervosa, Prader-willi syndrome 
4. Gastro intestinal disease (Wer et al 2008)47 ( Gonzalez ray 
et al)48 
5. Cardio vascular disease: Heart failure, dilated cardiomyopathy 
6. Osteoporosis 
7. Aging  
8. Chronic wasting syndrome - Cachexia, AIDS, post 
operative patients. 
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ROLE OF GHRELIN IN EPILEPSY: 
Ghrelin levels after epileptic seizures, results were 
controversial both in human and animals. 
Interplay between epilepsy and the endocrine system exist. 
And Epilepsy and antiepileptic drugs affect hormonal system and 
neuroendocrinal system. 
RELATION BETWEEN SLEEP AND EPILEPSY: 
Inadequate sleep is common in patients with epilepsy. It can 
result in impairment of quality of life and day time functioning. 
Inadequate sleep can exacerbate the daytime drowsiness and 
memory dysfunctions, which are common in these patients, and can 
contribute to seizures becomes intractable one. There is a vicious 
cycle of sleep disruption, worsening of seizures, and further 
impairment of sleep that can be responsible for intractability in 
epilepsy. 
The causes of sleep disruption in epileptic patients are so 
many and include inadequate sleep hygiene, insufficient sleep, 
circadian rhythm disturbances, and co existing sleep disorders. In 
epilepsy, presence of epilepsy itself, and usage of anticonvulsant 
drugs can disrupt the sleep and even seizures occurring during 
wakefulness can disrupt the sleep.  
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Causes of sleep disruption in epilepsy: 
Several studies have confirmed that sleep disorders and 
sleepiness are common epilepsy. 
De Haas et al showed that patients with partial seizures have 
twice the prevalence of sleep disturbances than controls and the 
sleep disturbance is associated with further worsening of quality of 
life. This study also explains sleep disturbance in epileptic patients 
are not related to number of antiepileptic drugs being taken, 
suggesting that sleep disturbance may be inherent to the disorder 
itself. 
Causes of sleep disruption in epilepsy: 
 
EFFECT OF SLEEP ON EPILEPSY: 
Relationship of sleep-wake state to epilepsy and IEDS  
(Inter-Ictal Epilepti form Discharges): 
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In 1885, Gower35 found that 42% of patients had seizures 
solely in awake state, 21% of patients had seizures during sleep, 
and 37% had seizures during both sleep and wake. The amount of 
baseline rhythmicity occurring in the brain differs between the state 
of sleep and wake time. 
Sleep has a pronounced effect on secondary generalization of 
partial seizures. IEDs are generally activated by NREM third 
and fourth stage in focal epilepsy and relatively suppressed by 
REM sleep). Malow et al., found that IEDs occurred frequently in 
deepened sleep (N3 sleep). Seizures in sleep also tend to occur 
during NREM sleep,) they are frequently observed in stage-2 
NREM sleep, followed by stage-1 and then stage-3 and stage-4. 
Minecin et al.,  examined seizure rates in various stages of sleep in 
epilepsy patients undergoing overnight polysomnography. A total 
of 55 patients included in that study 95% of seizures occurred in 
NREM stage (14% stage-3&4, 20% stage-1, 61% stage-2) and only 
5% of seizures in REM sleep. So from this they concluded that both 
IEDs and seizures are facilitated by NREM sleep. 
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MECHANISMS INFLUENCING SLEEP AND EPILEPSY 
NREM sleep represents a state of synchronization between 
thalamus and cortex and brain stem reticular activation system. The 
process of deepening of NREM sleep is correlated with reduction of 
effect of acetylcholine with progressive hyper polarization of 
neurons in the thalamocortical area. This hyper polarization in 
various levels may facilitate seizures and IEDs. REM sleep is 
characterized by inhibition of thalamocortical synchronyzing 
mechanism , inhibition of spread of epileptiform discharge, a 
desynchronized pattern of EEG, and skeletal muscle paralysis.  
Sleep disturbances associated with epileptic patients are 
diagnosed by using polysomnography. 
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Distribution of seizure frequency during sleep: 
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Epileptiform discharges  were noted mainly during stages 1 
and 2 sleep, whereas they were scantily present in slow-wave sleep. 
No epileptiform discharges were seen during REM sleep. 
Two state-specific components affecting epilepsy are the 
degree to which cellular discharge patterns are synchronized and 
alterations in antigravity muscle tone (Shouse MN et al 1996)36. 
REM sleep is also called paradoxical sleep because it is 
characterized by a highly active brain in a paralyzed body 
(Carskadon MA et al 2000)37. 
NREM sleep differs from REM sleep in that EEG activity is 
synchronized and postural muscle tone is decreased. REM sleep 
differs from NREM sleep in that EEG activity is desynchronized 
and also postural muscle tone is absent. 
During NREM sleep, every cell in the brain discharges 
synchronously, and the discharge may even reach paroxysmal levels 
similar to those in epileptic states. Synchronous synaptic effects, 
whether, excitatory or inhibitory, are agument the magnitude and 
propagation of postsynaptic responses, including epileptic 
discharges. During REM sleep, cells discharge asynchronously. The 
divergent synaptic signals associated with asynchronous discharge 
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patterns are less likely to augment the propagation of epileptic EEG 
discharges. 
Antigravity muscle tone is preserved in NREM sleep and 
waking, thus permitting seizure-associated and parasomnia- 
associated movement. But during REM sleep, profound lower 
motor neuron inhibition occur, it creats virtual paralysis (but 
diaphragm spared to permit continued respiration. Disruption of 
this component of REM sleep might underlie RBD and can 
influence clinically evident motor seizures. 
SLEEP DISORDERS ASSOCIATED WITH PATIENTS WITH 
EPILEPSY:  
Seizures may manifest as recurrent dreams, nightmares, or 
disorders of arousals such as sleep terrors and sleep walking. 
Autosomal dominant frontal epilepsy sometimes may also manifest 
as recurrent nightmares (Scheffer IE et al 1995)38.  
Common sleep disorders presents with epilepsy are excessive 
day time sleepiness; sleep disordered breathing, insomnia, 
nightmares, periodic limb movement disorder, disorders of arousal. 
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ROLE OF POLYSOMNOGRAPHY IN EPILEPSY: 
The main cause for referral in epileptic patients is excessive 
day time sleepiness, suspected obstructive sleep apnoea (OSA), and 
characterization of nocturnal spells. The most common 
polysomnographic finding in epilepsy is OSA, although also found 
narcolepsy, insufficient sleep syndrome with possible idiopathic 
hypersomnolence, and previously unrecognized nocturnal seizures. 
Beth A .Malow et al 199739, conducted a study about 
usefulness of polysomnography in epileptic patients found that 
some patients with OSA, treated with continuous positive airway 
pressure and treated with followup appointments. The majority of 
patients treated for OSA or other disorders have improvement in 
sleepiness or seizure control. It indicates the role polysomnography 
in epileptic patients. 
 52 
AIM & OBJECTIVE OF THE STUDY 
The primary aim of the study was to investigate the 
prevalence of sleep disturbances among generalized tonic-clonic 
patients and compare their polysomnography parameters with the 
normal controls and assessing their serum Ghrelin levels. 
OBJECTIVES:  
1. To assess the sleep changes and serum Ghrelin levels in 
patients with generalized tonic- clonic seizures.  
2. To compare the serum Ghrelin levels in patients with 
generalized tonic clonic seizures and normal persons. 
3. To correlate serum Ghrelin levels with sleep. 
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MATERIALS AND METHODS 
The study was conducted during the year 2014 at the Institute 
of Physiology and Experimental Medicine, Madras Medical College 
after getting approval from Institutional Ethics Committee (IEC), 
Madras Medical College Chennai. 
SELECTION OF SUBJECTS 
Thirty patients with generalized tonic clonic seizures of age 
group between 20-40yrs will participate in the study and thirty age 
matched apparently healthy persons selected from community will 
be controls. 
INCLUSION CRITERIA: 
Both men and women in the age group of 20 – 40 yrs 
diagnosed with generalized tonic clonic seizures. 
EXCLUSION CRITERIA: 
Patient with the following conditions were excluded from the study: 
• Children 
• Presence of any concurrent psychiatric disease 
• Conditions mimics epilepsy. 
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Other diseases (neurological, endocrinological, rheumatological, 
haematological, infectious disease, or inflammatory). 
• Kidney or liver dysfunction 
• Substance abuse  
• Sleep disorders  
• Controls were age matched healthy subjects with 
normal sleep habits. 
With these criteria a total of 60 male and female individuals 
of were selected, Of this 30 were Generalized –tonic clonic patients 
and remaining 30 were healthy age matched controls. After 
thorough explanation of the study, informed verbal and written 
consent was obtained from the participants, and polysomnography 
(PSG) was conducted when patient is in stable condition. 
STUDY DESIGN: cross sectional study 
TYPE OF STUDY: comparative study 
PLACE OF STUDY: Institute of Physiology and 
Experimental Medicine, Madras Medical College, Chennai 03 and 
Institute of Neurology, Rajiv Gandhi Govt. General Hospital, 
Chennai-3. 
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REQUIREMENTS FOR CONDUCTING 
POLYSOMNOGRAPHY 
• Air conditioned room with attached bathroom 
• Polysomnographic recording system  
• Computer 
• Amplifiers 
• Electrodes and application material 
• Pulse oxymeter-to detect blood gas analysis 
• Abdominal and thoracic belts-to detect respiratory effort 
• Nasal airway pressure transducer- to detect nasal airflow 
• Access to emergency medical care 
Figure 
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PRESTUDY PROCEDURE: 
• Detailed sleep wake history is taken 
• Complete medical history and clinical examination should be 
completed 
• Information is provided to the patient about the purpose and 
procedure of sleep study 
Patient should be made aware that their sleep will be 
monitored throughout the entire study and they should be told how 
to contact the technologist if necessary.  
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THE PATIENT WAS ASKED TO FOLLOW THE 
INSTRUCTIONS: 
• To take a bath in the evening and shave of facial hair  
• Not to apply oil anywhere on the body 
• To take dinner at least one hour before sleep study 
• Not to consume alcohol on the day of study 
• Avoid coffee or tea at least 3 hours before the study 
• Dress in routine sleep wear 
• Remove all ornaments 
• To bring all previous medical reports 
• Report for sleep study at the appointed time 
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PATIENT TRAY CONSISTS OF  
• EEG paste 
• Measuring tape 
• Cotton swabs 
• Electrodes, sensors, and lead wires 
• Spirit 
• Micropore 
• Gloves 
• Scissors 
• Emergency anticonvulsant drugs. 
DIGITAL SPECIFICATION FOR ROUTINE 
POLYSOMNOGRAPHY (AASM GUIDELINES) 
Electrode 
Desirable 
sample 
rate(Hz) 
Minimal 
sampling 
rate 
(Hz) 
High 
frequency 
filter 
(Hz) 
Low 
frequency 
filter 
(Hz) 
Maximum 
impedance 
(K Ohms) 
EEG 500 200 35 0.3 5 
EOG 500 200 35 0.3 5 
EMG 500 200 100 10  
EKG 500 200 70 0.3  
Snoring 500 200 100 10  
Airflow 100 25    
Oximetry 25 10    
Chest and 100 25    
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Electrode 
Desirable 
sample 
rate(Hz) 
Minimal 
sampling 
rate 
(Hz) 
High 
frequency 
filter 
(Hz) 
Low 
frequency 
filter 
(Hz) 
Maximum 
impedance 
(K Ohms) 
abdominal 
movement 
Body 
position 
1 1    
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SIGNAL MEASUREMENT 
The recorded signal can be measured according to  
a. Frequency- frequency is described as cycles per second or 
Hertz which refers to the number of waves appearing in 
the span of one second. 
b. Amplitude – Amplitude refers to the vertical height of a 
wave and represents electrical voltage of the wave. It 
depends on the sensitivity setting of amplifier .  
Sensitivity is defined as the amount of voltage necessary to 
produce a set deflection of the pen. Greater the sensitivity, lesser is 
the recorded amplitude. 
SLEEP STUDY PROCEDURE: 
Patient hookup: - It involves placement of various sensors to 
record the different parameters during sleep. 
STEPS IN INTERNATIONAL 10-20 ELECTRODE 
PLACEMENT SYSTEM 
International 10-20 system was developed as a standard 
measurement tool for placing electrodes on the head for recording 
EEG. The following electrode sites are located according to R&K 40 
criteria-two mastoid (known as aural, A1 and A2), two central (C3 
and C4) and two occipital derivations (O1&O2). EEG is recorded 
using either gold cup or silver chloride electrodes. 
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Location for four landmarks-nasion, inion, left preauricular 
region , and right preauricular region. 
The distance from nasion to inion was measured. The 10 % of 
total distance from nasion is marked as Fpz and from inion as Oz 
along the line joining them. The halfway point between nasion and 
inion is marked as Cz. 20 % distance from Cz in front is marked as 
Fz and back as Pz. 
The distance between left and right preauricular point was 
measure, with the tape passing through the halfway mark of Cz. 
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From the Cz 20 % of the distance on the left is marked as C3 and 
right as C4 on the line joining the left and right preauricular points. 
The circumference of the head is measured by passing the 
through all the 10% marks. 50% of this measurement coincides 
with Oz at the back and Fpz in the front. 5% of circumference to 
the left of Oz is marked as O1and right as O2. Similarly 5% 
circumference to left of Fpz is marked as Fp1 and right as Fp2. 
The distance from Fp1 to O1 passing through C3 is measured. 
50%of this distance should intersect at C3. 25% of this distance is 
marked on the line joining Fp1and C3 as F3 and similarly on the 
right side as F4. 
A1 and A2 are placed behind the ears on the mastoid process. 
For recording the electro oculogram, the placement of an 
electrode is located 1 cm out and below the outer canthus of the left 
eye (E1) and another electrode placed 1 cm out and above the  outer 
canthus of right eye (E2) with reference to the right mastoid 
process (A2). It records the retino- corneal potential difference . 
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For recording the electromyogram of the chin ,two electrodes 
are placed just below the chin , one electrode placed 2cm below and 
2cm left of midline and the others is 2cm below and 2cm to the 
right of midline. 
Respiratory effort belts are placed snugly around the thorax 
and abdomen. 
Airflow sensors- Nasal prongs connected to a pressure 
transducer is used for measuring nasal flow (gives an indirect 
measure of flow based on the recording of the pressure at the gives 
an indirect measure of flow based on the recording of the pressure 
at the prongs relative to the atmospheric pressure.) 
Oximeter sensor is placed on any of the three middle fingers . 
it is a noninvasive method for monitoring the hemoglobin 
percentage saturated with oxygen. Snore sensor is also connected. 
Leg EMG leads records activity of anterior tibialis muscle. 
Electrodes are placed on the outer aspect of lower half of each leg. 
PARAMETERS RECORDED: 
• ELECTROENCEPHALOGRAM 
• CHIN ELECTROMYOGRAM 
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• ELECTRO OCULOGRAM 
• ELECTROCARDIOGRAM 
• AIRFLOW 
• ABDOMINAL AND THORACIC RESPIRATORY EFFORT 
• LEG/ARM ELECTROMYOGRAM 
• SATURATION 
• SNORING 
• BODY POSITION 
• HEART RATE 
After all sensors are applied start the study and check the 
impedance and signal of all the electrodes. Perform biocalibration –
at the start of the study before lights out and just after lights on at 
the end of the study. 
Close eyes-instruct patient to lie down with eyes closed for 
30 seconds. This helps to reveal the alpha activity. 
Open eyes-instruct patient to lie still down with eyes open for 
30 seconds. This helps to eliminate the alpha activity. 
Look left and right- instruct patient to look to left and right 
repeatedly while holding the head still. This mimics the eye 
movement seen during REM sleep 
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Look up and down- instruct patient to look to the up and 
down repeatedly while holding the head still. This differentiates the 
vertical and horizontal eye movements. 
Hold breath-Instruct the patient to take a deep breath and hold 
it for 5-10 seconds. This mimics the central apnoea 
Respiratory effort- Instruct he patient to move the chest and 
abdomen in and out while holding breath. This mimics an 
obstructive apnoea. 
Move feet- Instruct the patient to move the feet. This mimics 
leg movements during sleep. 
During the study the observer should document 
Time of sleep study 
• Biocalibration 
• Technical difficulties and methods of correction 
• Patient complaints 
Post study procedure 
• Ensure that study is saved properly 
• Clean and sterilize the electrodes and various sensors 
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SCORING AND DATA ANALYSIS IS DONE TO RECOGNIZE 
THE FOLLOWING EVENTS 
• Sleep staging 
• Arousal 
• Cardiac events 
• Respiratory events 
• Movement events 
SCORING BY EPOCHS 
The polygraph record is divided into segments of equal size, 
with epoch length of 300mm and duration of 30 seconds. 
A single stage score is assigned to each epoch-when more 
than one stage is present in each epoch-the stage score of the epoch 
is determined by the stage that takes up the greatest portion of the 
epoch. 
SLEEP STAGES SCORING: 
Sleep stage are scored at 30 sec sequential recordings known 
as epochs. 
Wake – A>50% of an epoch has alpha EEG waves over the 
occipital region with eye closure or if alpha waves absent the 
presence of any of the following Eye blinks (0.5-2Hz) 
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Reading eye movement which consists of slow conjugate 
movement followed by a rapid movement in the opposite direction, 
Rapid open eye movements associated with normal or high chin 
tone.  
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Figure   Epoch of awake stage 
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Figure   Epoch of stage N1 
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Figure   Epoch of stage N2 
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Figure   Epoch of stage N3 
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Figure   Epoch of stage REM 
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Stage-I- alpha waves being replaced by a low amplitude , 
mixed frequency (4 to 7Hz) waves occupying >50% of the epoch, 
or the presence of (for those who do not generate alpha waves) 
Vertex sharp waves of <0.5 seconds duration that are 
maximal over central region 
Slow eye movement 
Stage II- defined by the presence of K complexes or sleep spindles. 
Stage III and IV – indicated when >=20%of the epoch shows slow 
wave (0.5-2Hz and >75uV) EEG activity. 
REM – presence of low amplitude, mixed frequency EEG activity, 
rapid eye movement on EOG, and low tone on EMG. 
RESPIRATORY EVENTS SCORING RULES: 
APNOEA-decrease in airflow amplitude by => 90% from 
baseline for duration of minimum10 seconds. It is scored as 
Obstructive-If inspiratory effort is present throughout the entire 
period 
Central -If the inspiratory effort is absent throughout the period 
Mixed –If inspiratory effort in the initial part of the period is 
followed by the presence of inspiratory effort. 
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Hypoapnoea-decrease in airflow amplitude by =>30% of 
baseline for a duration of at least 10 seconds accompanied by =>4% 
of oxygen saturation. 
Arousal 
During NREM sleep – abrupt frequency shift (eg.alpha , theta 
or frequencies >16 Hz) lasting =>3 seconds and preceded by =>10 
seconds of stable sleep. 
During REM sleep abrupt EEG frequency shift (e.g alpha, 
theta, or frequencies >16 Hz) lasting =>3 seconds and  preceded by 
=>10 seconds of stable sleep, accompanied by an increase in chin 
EMG that is =>1 second duration. 
Respiratory Effort Related Arousal (RERA)- breaths 
associated with heightened respiratory efforts or flat  airflow 
waveform with a duration =>10 seconds and preceding an arousal 
but not meeting criteria for either apnoea or Hypoapnoea. 
Periodic limb movement in sleep 
Four consecutive leg movements (each 0.5 to 10 seconds in 
duration with an amplitude 8uV above resting EMG) characterized 
by period lengths of between 5 and 90 seconds between onset of 
consecutive movements. 
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Leg movements on different legs are counted as one movement if 
they are separated by <5 seconds between movement onsets. 
Cardiac events scoring rules 
• Asystole-cardiac pause >3 seconds 
• Bradycardia- heart rate <40 beats per minute 
• Sinus tachycardia-heart rate>90 beats per minute 
SLEEP ARCHITECHTURE DEFINITION AND FORMULAE 
• % Stage I = Minutes of Stage I *100/ Total Sleep Time (TST) 
• % Stage II   = Minutes of Stage II *100/ Total Sleep Time (TST) 
• % Stage III & IV = Minutes of Stage III&IV *100/ Total 
Sleep Time (TST) 
•  % Stage R = Minutes of Stage R *100/ Total Sleep Time 
(TST) 
• % Wake time=Minutes of Wake *100/ Sleep Period Time (SPT) 
• Sleep Onset = the first three consecutive Epochs of Stage I 
sleep 
• Latency to REM= the period of time from sleep onset to first 
Epoch of     REM 
• NAP onset (Sleep) latency= the period of time to lights out to 
sleep onset 
• Sleep Period Time (SPT) = the time from sleep onset to last 
Epoch of sleep 
• Total Recording Time (TRT) - The time from lights out to lights 
on  
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• Total Sleep Time (TST) - The amount of sleep recorded during 
TRT 
• Wakefulness After Sleep Onset (WASO) - The Wakefulness 
occurring from sleep onset to last Epoch of sleep 
OTHER INDICES 
Apnoea Hypoapnoea Index (AHI) - Total number of apnoeas and 
Hypoapnoeas occurring per hour of sleep 
Respiratory Disturbances Index (RDI)- Total number of apnoeas 
and Hypoapnoeas and Respiratory Effort Related Arousals occurring 
per hour of sleep 
Desaturation Index (DI)- Total number of desaturation events per 
hour of sleep 
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4.3.2 STORAGE OF SAMPLES 
A well maintained deep freezer with -20 degree c was 
available in the Institute of Physiology and Experimental Medicine, 
Madras Medical College, Chennai. All the samples were stored in 
the deep freezer until estimation of serum ghrelin. 
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ESTIMATION SERUM GHRELIN: 
Estimation was done using Human Ghrelin ELISA kit  
Contents of the kit  
    1. Wash buffer 
    2. Lyophilized anti-Ghrelin polyclonal antibody 
    3. Standard 
    4. TMB substrate 
    5. Stop solution 
    6. Sample diluent 
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ASSAY PROCEDURE:  
a. Preparation of reagents, samples and standards done.  
b. Add 100 µl anti-Ghrelin antibodies to each well. Incubate 1.5 
hours at room temperature.  
c. Next add 100 µl standard or sample to each well. Incubate 2.5 
hours at room temperature.  
d. Then add 100 µl prepared streptavidin solution. Incubate 45 
minutes at room temperature.  
e. Then add 100 µl TMB One-Step Substrate Reagent to each well. 
Incubate 30 minutes at room temperature.  
f. Then add 50 µl Stop Solution to each well. Read at 450 nm immediately  
CALCULATION OF RESULTS:  
Calculate the mean absorbance for each set of duplicate 
standards, controls and samples, and subtract the blank optical 
density. Plot the standard curve using Sigma Plot software (or other 
software which can perform four-parameter logistic regression 
models), with standard concentration on the x-axis and percentage 
of absorbance on the y-axis. Draw the best-fit curve through the 
standard points. (Ray Bio Human Ghrelin EIA Kit Protocol) 
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• Percentage absorbance = (B – blank OD)/ (Bo – blank OD)  
where  
• B = OD of sample or standard and  
• Bo = OD of zero standard (total binding 
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RESULTS 
The data obtained from conducting the polysomnography and 
serum ghrelin were statistically analysed using the statistical 
package for social sciences (SPSS) software version 21. From the 
data, mean and standard deviation of the variables are determined 
for the individual groups. Student t testswas employed for 
statistical analysis. 
• *P value < 0.05 was considered as significant. 
• *P value < 0.01 was considered as highly significant 
• *P value < 0.001 was considered as very highly significant. 
COMPARISON OF AGE AND BMI: 
In the two study groups, age is compared and the results 
shown in the table 5.1. The mean age of control group is 
30.03±6.26, and that of GTCS group is 31.10±5.60. The difference 
between the age group is found to be statistically not significant ( p 
value 0.4), and mean BMI of control group is 26.30±1.46 and that 
of GTCS  group is 26.89±0.99. The BMI was found to be 
statistically not significant (p value 0.06). 
               
 86 
TABLE I: Comparison of parameters between Control and GTCS 
patients 
Variable Group N Mean 
GTCS 30 31.10±5.60 
Age 
CONTROL 30 30.03±6.26 
GTCS 30 26.89±0.99 
BMI 
CONTROL 30 26.30±1.46 
 COMPARISON OF SLEEP EFFICIENCY/ NAP STATUS: 
The NAP status percentage of study groups was measured and 
statistically analysed and the results are shown in table 5.2. 
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TABLE II: Comparison of Sleep Efficiency/ NAP status  between 
Control and GTCS patients 
Variable Group N Mean SD P –Value 
Control 30 91.58 3.66 SLEEP EFFECIENCY 
% GTCS 30 84.58 7.20 
<0.000* 
   P – Value < 0.001 very highly significant. 
The NAP status percentage of GTCS patients shows a very 
highly significant decrease (** p value < 0.000) when compared to 
control groups. 
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COMPARISON OF SLEEP STAGE I: 
TABLE III: Comparison of Sleep Stage I between Control and GTCS 
patients 
The difference between the sleep stage I duration in study 
groups is statistically  very highly significant. 
COMPARISON OF SLEEP STAGE II:      
TABLE IV: Comparison of Sleep Stage II  between Control and GTCS 
patients                  
Variable Group N Mean SD P -Value 
Control 30 197.5 22 Sleep stage II 
(Minutes) GTCS 30 211.6 16.26 
<0.006* 
*    P – Value < 0.001 is  very highly Significant 
 
The difference between the sleep stage II duration in study 
groups is statistically  very highly significant. 
Variable Group N Mean SD P –Value 
Control 30 14.6 2.60 Sleep stage I 
(Minutes) GTCS 30 18.35 2.85 
<0.000* 
*    P – Value  < 0.001 very highly Significant 
 89 
 
 
 
 
 
 90 
COMPARISON OF SLEEP STAGE III:   
TABLE V: Comparison of Sleep Stage III  between Control and GTCS 
patients 
Variable Group N Mean SD P –Value 
Control 30 40.9 7.20 Sleep stage III 
(Minutes) GTCS 30 36.98 7.40 
<0.042* 
*    P – Value < 0.05 is Significant. 
The sleep stage III of GTCS group shows a significant 
decrease (p value 0.042) when compared to control group. 
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COMPARISON OF SLEEP STAGE IV: 
TABLE VI: Comparison of Sleep Stage IV between Control and GTCS 
patients 
Variable Group N Mean SD P –Value 
Control 30 43.9 11 Sleep stage IV 
(Minutes) GTCS 30 42.65 9.22 
<0.6 
*    P – Value  < 0.05 Significant 
The sleep stage IV of GTCS group shows a decrease but not a 
significant decrease (p value 0.042) when compared to control 
group. 
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COMPARISON OF REM SLEEP STAGE: 
TABLE VII: Comparison of REM Sleep Stage between Control and 
GTCS patients 
Variable Group N Mean SD P –Value 
Control 30 77.27 13.3 
REM Sleep Stage (Minutes) 
GTCS 30 63.93 13.21 
<0.000* 
**    P – Value  < 0.001 very highly Significant 
The REM sleep stage of GTCS group shows a significant 
decrease (p value< 0.000) when compared to control group. 
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COMPARISON OF NREM SLEEP: 
TABLE VIII: Comparison of NREM sleep between Control and GTCS 
patients 
Variable Group N Mean SD 
P –
Value 
Control 30 296.8 69.2 
NREM sleep (Minutes) 
GTCS 30 309.52       20.5 
<0.3 
*    P – Value  <0.05 is  Significant 
The difference between the NREM sleep stage is in between 
study groups is statistically not significant. 
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COMPARISON OF SLEEP STAGE PERCENTAGE: 
TABLE IX: Comparison of Sleep Stage Percentage between  Control 
and GTCS patients 
Variable Group Mean SD P –Value 
Control 3.90 0.66 Stage I % 
(Stage I/Total Sleep 
Time*100) GTCS 4.92 0.68 
<0.000* 
Control 52.74 4.12 Stage II % 
(Stage II/Total Sleep 
Time*100) GTCS 56.73 3.13 
<0.000* 
 
Control 10.97 1.88 Stage III % 
(Stage III /Total Sleep 
Time*100) GTCS 9.88 1.90 
<0.02* 
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Variable Group Mean SD P –Value 
Control 11.73 2.61 Stage IV % 
(Stage  IV/Total Sleep 
Time*100) GTCS 11.45 2.51 
<0.67 
Control 20.66 3.20 REM % 
(REM/Total Sleep Time*100) GTCS 17.02 2.78 
<0.000* 
*    P – Value  < 0.05 Significant 
**    P – Value  < 0.001 Very Highly Significant 
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COMPARISON OF TOTAL SLEEP TIME/ NAP TIME: 
TABLE X: Comparison of Total sleep time/ Nap time Control and 
GTCS patients 
Variable Group N Mean SD 
P –
Value 
Control 30 374.08 28.15 
Total sleep time (Minutes) 
GTCS 30 373.53 27.97 
<0.93 
*    P – Value  < 0.05 Significant 
The NAP time of GTCS group shows a decrease, but not a 
significant (p value< 0.93) when compared to control group. 
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COMPARISON OF NAP ONSET LATENCY: 
TABLE XI: Comparison of NAP onset latency between Control and 
GTCS patients 
Variable Group N Mean SD 
P –
Value 
Control 30 14.37 5.9 
NAP onset latency (Minutes) 
GTCS 30 15.52 5.9 
<0.4 
   * P – Value  < 0.05  Significant 
 
The NAP onset latency of GTCS group shows a decrease, but 
not a significant (p value< 0.4) when compared to control group. 
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COMPARISON OF SUBJECTIVE SLEEP SCORES: 
TABLE XII: Comparison of subjective sleep scores between Control 
and GTCS patients 
Variable Subjects Questionnaires mean SD P –Value 
Control PSQI 0.77 1.33 
GTCS PSQI 4 2.69 
0.000** 
Control ESS 6.23 2.21 
Subjective 
sleep scores 
GTCS ESS 8.56 4.22 
0.009* 
* P value < 0.001 very highly significant 
**    P – Value  < 0.001 Very Highly Significant 
The difference between subjective sleep score in between 
study groups is statistically significant. 
COMPARISON OF SERUM GHRELIN LEVELS 
TABLE XIII: Comparison of serum ghrelin levels in between Control 
and GTCS patients 
Variable Group N Mean SD P –Value 
Control 30 191.6 30.5 
Serum ghrelin(ng/ml) 
GTCS 30 92.6 25.5 
<0.000* 
*    P – Value  < 0.001 is very highly Significant 
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DISCUSSION 
This study was done to record sleep stages and events 
occurring during sleep and find the serum ghrelin levels in both 
generalized tonic clonic seizure patients and in control groups 
along with their subjective sleep scores. The mean age of the study 
groups were comparable 31.10±5.6 for GTCS patients and 
30.03±6.26 for control groups as well as body mass index for GTCS 
patients (26.89±0.99) and for control groups (26.30±1.46). Both the 
group persons were subjected to polysomnography for a minimum 
period of 6 hours to maximum period of 8 hours. The obtained data 
were analyzed statistically and student’t test was used to obtain the 
significance. 
SCORING OF SLEEP STAGES: 
Sleep stages were interpreted with respect to the duration of 
each sleep stage, sleep onset latency, total sleep duration, sleep 
efficiency. Total sleep time was recorded as the sum of all 30 
second epochs of REM and non REM sleep. The mean total sleep 
time (NAP time) for GTCS patients 373.53±27.97 and for control 
group 374.08±28.15 minutes. 
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The mean sleep efficiency percentage of GTCS patients 
shows a very highly significant decrease 84.58±7.20 when 
compared to control group 91.58±3.66%. this may be the cause of 
sleep disruption in patients with epilepsy. 
Sleep stage I of GTCS patients 18.35±2.85 minutes of mean 
value shows an highly significant increase when compared to 
control groups 14.6±2.6 minutes. Similar increase in first stage of 
sleep was obtained in the study done by (Maganti R et al 2005)41. 
Sleep stage II of GTCS patients 211.6±16.26 minutes of mean value 
shows a significant increase when compared to control groups 
197.5±22 minutes. Excessive day time sleepiness is associated with 
increase in sleep stage I, increased arousal frequency leading to 
loss of continuity in sleep, decrease in duration of slow wave sleep 
and REM sleep. 
Sleep stage III of GTCS shows a significant decrease 
36.98±7.40 when compared to control group 40.9±7.2 minutes. 
Sleep stage IV of GTCS patients shows a decrease 42.65±9.22 but 
not a significant when compared to control group, 43.9±11 minutes. 
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Rapid eye movement sleep stage of GTCS patients shows a very 
highly significant decrease 63.93±13.21 when compared to control 
groups 77.27±13.3 minutes. Similar results were obtained in the study 
done by (Maganti R et al 2005).41 
NAP onset latency is defined as the duration of time between 
lights out and sleep onset, defined by consecutive epochs of stage I 
or first stage of deeper NREM stage. The NAP onset latency 
measured in minutes for GTCS 15.52±5.9 shows an increase but not 
significant, when compared control groups 14.37±5.9 minutes. 
Baldy-Moulini et al 72, conducted a study, childhood absence 
epilepsy, described several changes in sleep architecture including 
increased sleep latency, REM latency, REM percentage, and 
increased awakenings. 
The mean percentage value of the sleep stages showed 
reduction in deep slow wave sleep and rapid eye movement stage, 
there by occupying the counter portion by the stage I & II as the 
following; Sleep stage I GTCS patients 4.93±0.68%, control group 
3.90±0.66%, Sleep stage II GTCS patients 56.73±3.13%, control 
group 52.74±4.12%, Sleep stage III GTCS patients 9.88±1.90%, 
control group 10.97±1.88%, Sleep stage IV GTCS patients 
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11.45±2.51%, control group 11.73±2.61%, stage REM GTCS 
patients 17.02±2.78%, control group 20.66±3.20%. The slow wave 
sleep is reduced and the part is occupied by stage 1&2 of sleep. 
Epileptiform discharges may themselves disrupt the quality of 
sleep and result in a chronically sleep-deprived state. The 
epileptiform discharges were primarily distributed in stages 1 and 2 
of sleep, whereas they were rarely present during wakefulness and 
slow-wave sleep, and scoring in slow-wave sleep was technically 
difficult. Sleep deprivation resulting from such disruption in either 
the short term or the long term can facilitate seizures and 
epileptiform discharges (Maganti R et al 2005)41. 
Sleep architecture changes were, however, more significant 
when patients had nocturnal seizures compared with those who had 
no seizures (Besset A et al) 73. 
PSG studies of adults with focal epilepsy showed mixed results. 
In temporal lobe epilepsy, for example, reduced sleep efficiency and 
REM sleep and increased wakefulness after sleep onset and lighter 
stages of sleep were found, especially with diurnal and nocturnal 
seizures (Baldy-Moulinier et al74 and Bazil.cw et al75).  
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In frontal lobe epilepsy, reduced sleep efficiency and 
increased ratio of cyclic alternating pattern duration to non-REM 
sleep was noted (Crespel A et al76 and Zucconi et al77).  
Others have shown that sleep architecture can be abnormal in 
patients with focal epilepsy, even in the absence of clinical 
seizures, because interictal discharges can themselves cause 
repeated arousals.78,79Cortx F et al and Dahire et al. 
Subjective sleep scores for GTCS patients 4±2.69 for PSQI 
were higher than for the control group 0.77±1.33, as well as higher 
scores for ESS obtained for shift worker 8.56±4.22 as compared to 
control group 6.23±2.21, showing poor quality of sleep for GTCS 
patients and more prone for dozing during the period when he or 
she usually is awake.  
In my study, Serum ghrelin levels in GTCS patients shows a 
highly significant decrease 92.6±25.5 ng/ml, when compared with 
control group 191.6±30.5 ng/ml. These results were consistent with 
the study by Z.Ataie et al 201042. 
These results also consistent with, studies conducted by 
(Greco et al 200543, Prodam et al 2010) Circulating ghrelin levels 
were significantly lower in epileptic patients treated with valproate 
in pubertal and pre pubertal periods. 
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Aydin. S et al 200944 and Dag E et al 201045 conducted 
studies shows that both acylated and deacylated forms of serum and 
salivary ghrelin were depressed in epileptic patients before and 
after treatment with respect to normal controls. 
Contradictorily, Berilgen M.S et al 2006 demonstrated that 
ghrelin levels were higher in epilepsy patients who received 
antiepileptic drug therapy than a control group. These results also 
demonstrated by, Gungor.S et al 200746 and Tomoum.H.Y et al 
200947 in children treated with valproate in comparison with 
healthy controls. 
Z. Ataie et al 2011 conducted a study, its results shows 
ghrelin levels reduced following seizures in rats.  
Two possibilities may be considered for this lowered ghrelin 
levels after seizures. 
1. Uptake of Acylated ghrelin is increased by central nervous system 
structures to modulate epileptic discharges.  
2. A feedback system reduces the ghrelin levels after seizures. 
In this feedback regulating mechanism, some hormones are involved 
in this action includes Somatostatin and Leptin. 
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Somatostatin is a peptide produced in the brain, pancreas, 
gastrointestinal system (Shimada et al 2003)48 .It is released 
mainly from neurons under conditions of elevated activity such as 
seizures (Vezzani, A et al 1999)49. A single injection of 
somatostatin reduces the concentration of ghrelin in rats. In 
addition, somatostatin decreases GOAT expression, enzyme 
responsible for acylation of ghrelin (Gahete, M.D et al 2010)50. 
Therefore, it is possible that blood acylated ghrelin reduction is due 
to somatostatin released from one of its source following seizures. 
The second possibility for this reduced ghrelin levels is high 
serum leptin levels following seizures, demonstrated in rats by Bhatt, R 
et al 2000551 and Hum, K.M et al 200952. In this study results shows 
that, approximately leptin levels increased as twice as controls (Hum, 
K.M et al 200952). On other hand, ghrelin is negatively regulated by 
leptin (Asakawa, A et al 200153) and physiological concentrations of 
leptin and hyperleptinemia directly inhibit the ghrelin secretion from the 
rat stomach (Kamegai, J et al 200454). Therefore ghrelin reduction 
might be due to release of leptin following PTZ induced seizures.  
Another possibility for this decreased ghrelin levels are 
human ghrelin exhibits saturable binding  and endocytosis in the 
RBE4 rat cerebral microvessel endothelial cell line (Pan, W et al 
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2006)55. And blood brain barrier mechanisms regulating ghrelin 
accumulation by brain may be influenced by pathophysiological 
events. It has also been shown that ghrelin and its agonists can be 
considered as an antiepileptic agent in rodents (). Therefore 
reduction of this ghrelin levels followed by PTZ induced seizure 
could be attributed to its uptake by brain to represent an anti-
epileptic effect.  
One more possibility for this reduced ghrelin following 
seizures are degradation and proteolysis of acylated ghrelin into 
non-Unacylated ghrelin metabolites could be occurred during 
seizures (De V riese, C et al 2004)56. 
M. Said Berilgen et al 200557, conducted a study and his 
results shows that serum ghrelin levels were enhanced following a 
seizure episode. Cause of this elevated ghrelin after the seizures 
may be due to changes in growth hormone and prolactin levels after 
seizures and there by disrupting equilibrium of hormones, may 
facilitate the occurrence of seizures.  
In humans, ghrelin act as an important factor in the sleep 
regulation.  
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A study conducted by Weikel, J.C et al 200358, its result 
shows that after an injection of ghrelin to normal healthy males, 
their slow wave sleep increased during night leads to non-REM 
sleep increased overall during the nigh. Stages of sleep are related 
to patterns of sleep occurrence. Epileptiform discharges multiply 
during non REM sleep stage. It is characterized by background of 
synchronized cellular discharges and reduced tone, which are also a 
sign of decreased wakefulness. In contrast, REM sleep resists the 
generation of epileptiform discharges (Shouse, M.N et al 2002)59. 
Ghrelin secretion in healthy, non obese persons shows a 
diurnal course and that during night its level elevated (Vaughn, 
B.V et al 2004) 60  
According to this study, ghrelin has a capacity to prolong the 
NREM sleep –the stage in which seizures occur, and also this 
elevated ghrelin level in these epileptic patients be interpreted as a 
contributing factor in the occurrence of seizure. Ghrelin levels 
elevated more in partial epilepsy than generalized epilepsy. The 
reason for these elevation may be due to most localized seizures 
originated from the temporolimbic structures that include amygdala 
and  hippocampus(Falconer, M.A et al 2964)61. Epileptiform 
discharges causes dysfunction in the temporolimbic region  has 
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been shown to disrupt the hypothalamo pituitary regulation 
(Herzog, A.G et al  1989 62and Bilo. L, et al 1991 63).This 
suggests that higher ghrelin levels were observed in these patients 
with partial epilepsy are mediated by the effects of epileptiform 
discharges on the regulation of ghrelin by hypothalamus. 
The use of antiepileptic drugs in this study patients, also may 
contribute to this elevated ghrelin levels. 
The capacity of epilepsy to impair regulation in the 
hypothalamo pituitary axis independent of medication has been 
reported (Zobel, A et al 2004)64. Based on this study suggest that, 
ghrelin capacity to affect sleep stages and neuroendocrine 
physiology, both of which are linked to epilepsy, it may be 
suggested that higher ghrelin levels found in these patients indicate 
the predisposition towards seizures.   
EFFECT OF AED’s IN SLEEP ARCHITECTURE: 
Although abnormalities in sleep architecture might be caused 
by anti epileptic drugs (AEDs), the results of studies are mixed. 
PHT, CBZ, Gabapentin (GBP), and Lamotrigine (LTG) have all 
been shown to affect sleep architecture (Placidi F et al)80, although 
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others have shown that AEDs improve sleep quality by reducing the 
interictal discharges and EEG arousals (Sammarilano M et al)81. 
Excessive daytime sleepiness was documented in de novo 
patients with epilepsy before AEDs were initiated and after 
sustained discontinuation (Wolf P et al)82.  
Majority of patients Data on effects of VPA on sleep structure 
are not consistent. VPA is known to have some hypnotic 
properties; it has been shown not to alter the sleep architecture 
itself by some researchers (Placidi F et al)80, whereas other studies 
have shown that it may reduce REM sleep (Lagros B et al)83or 
increase stage 1 sleep (Palm L et al)84.  
Sleep architecture can be abnormal in children with epilepsy, 
an abnormality that may be independent of AED effect. It also is 
possible that the behavioural abnormalities may have been due to 
AEDs as well.  
Several studies have shown that behavioural effects may 
be caused by a variety of AEDs, but literature in this area is 
confounded by inconsistent and contradictory results. Therefore no 
consistent conclusions can be made in this regard (Blaise B et al)85. 
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A study of children with newly diagnosed idiopathic 
generalized epilepsy before and after treatment may answer this 
question, but the study would be confounded by behavioral and 
attentional abnormalities caused by untreated epilepsy, and 
therefore methodologically difficult.  
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CONCLUSION 
The following conclusions have been derived from the study 
• Sleep efficiency percentage is significantly reduced in 
GTCS patients. 
• Stage I and II sleep duration and percentage 
significantly increased signifying increased duration of 
light sleep and more propensity for arousal and sleep 
disruption in GTCS patients. 
• There is significant decrease in percentage of REM 
sleep duration in GTCS patients. The lack of adequate 
deep sleep stages might be the underlying reason for the 
individual to wake up unrefreshed after his nocturnal 
sleep period. 
• In conclusion, results obtained from my study showed 
that serum ghrelin level significantly reduced in GTCS 
patients than comparative with control group.  
• Sleep architecture is abnormal in patients with 
generalized epilepsy. Further studies are needed to 
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determine whether abnormalities in sleep architecture 
contribute to poor daytime behaviour and attention. 
• In the future, a better understanding of the mechanisms 
responsible for seizure – induced alterations in hormone 
levels of plasma may help to prevent these changes. 
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LIMITATIONS 
• The main limitation of my study is that we were unable to 
control the medication effects. 
• Sample size is an important limiting factor in this study. 
• Only few numbers of prior studies available. Ghrelin 
hormone  is still under in research.. 
• Associated sleep disorders, it may also creates changes in the 
sleep architecture. 
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SUMMARY 
• This study was conducted to assess sleep and the sleep 
parameters in generalized tonic clonic patients in comparison 
with control group. 
• Thirty GTCS patients and thirty healthy control patients 
participated in the study. The results were statistically analyzed 
and tabulated for discussion. 
• Serum ghrelin levels were decreased significantly in these 
patients than compared with control group.  
• It was found that generalized tonic- clonic seizure patients have 
changes in the sleep pattern in the form of prolonged stage I and 
stage II of sleep with reduced REM sleep duration and sleep 
efficiency leads to fragmentation of sleep. Prolonged non REM 
sleep is an important precipitating factor for seizure propagation. 
• Due to the complex relationship between the epilepsy and sleep 
disorders, these sleep changes must be addressed in order to 
provide the best management of sleep disturbance in patients 
with epilepsy.  
BIBLIOGRAPHY 
1) Foldvary -Schaefer and Grigg - Damberger.Sleep complaints 
and epilepsy. 2009. 
2) Weikel,J.C., Wichniak,A.,Ising, M.,Brunner,H., Friess, E., 
Held, K. et al. Ghrelin promotes  slow-wave sleep in humans. 
Am J Physiol Endocrinol Metab.2003:284:E407-E415. 
3) Temkin O.The falling sickness: a history of epilepsy from the 
Greeks to the beginnings of modern neurology 1971. 3) 
Thurman, DJ; Beghi, E; Begley, CE; Berg, AT; Buchhalter, 
JR; Ding, D; Hesdorffer, DC; Hauser, WA; Kazis, L; Kobau, 
R; Kroner, B; Labiner, D; Liow, K; Logroscino, ILAE 
Commission on, Epidemiology (September 2011). "Standards 
for epidemiologic studies and surveillance of epilepsy.". 
Epilepsia. 52 Suppl 7: 2–26. 
4) Eadie MJ, Bladin PF. A disease once sacred- a history of the 
medical understanding of epilepsy.2001 
5) Berger H, Gloos p. Hans Berger and the electroencephalogram 
in man,1969. 
6) Thurman, DJ; Beghi, E; Begley, CE; Berg, AT; Buchhalter, 
JR; Ding, D; Hesdorffer, DC; Hauser, WA; Kazis, L; Kobau, 
R; Kroner, B; Labiner, D; Liow, K; Logroscino, ILAE 
Commission on, Epidemiology (September 2011). "Standards 
for epidemiologic studies and surveillance of epilepsy.". 
Epilepsia. 52 Suppl 7: 2–26. 
7) Harrisons text book of internal medicine.18th edition. 
8) Howard AD, , Cully DF, Arena JP, Liberator PA, Rosenblum 
CI, Hamelin M, , , Anderson J, Paress PS, Diaz C, Chou M, 
Liu KK, McKee KK, Pong SS, Griffin PR, A, Gupta SK, 
Schaeffer JM, Smith RG, Vander Ploeg LH (August 1996) "A 
receptor in pituitary and hypothalamus that functions in 
growth hormone release". 273 (5277): 974–7.  
9) Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, 
Kangawa K (1999). "Ghrelin is a growth-hormone-releasing 
acylated peptide from stomach". Nature 402 (6762): 656–60. 
10) Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, 
Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE. 
(2008) Ghrelin octanoylation mediated by an orphan lipid 
transferase. Proc Natl Acad Sci U S A  105:6320–6325. 
11) Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. (2008) 
Identification of the acyltransferase that octanoylates ghrelin, 
an appetite-stimulating peptide hormone. Cell 132:387–396. 
12) Inhoff T, Stengel A, Peter L, Goebel M, Taché Y, Bannert N, 
Wiedenmann B, Klapp BF, Mönnikes H, Kobelt P (2010).  
13) Grube D, Forssmann WG (1979) "Morphology and function 
of the entero-endocrine cells". Horm. Metab. Res. 11 (11): 
589–60623. 
14) Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, 
Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, 
Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK 
(2005) "Mice lacking ghrelin receptors resist the development 
of diet-induced obesity". J. Clin. Invest. 115 (12): 3564–72. 
Doi :10.1172/JCI26002. PMC 1297251 
15) Seim I, Walpole C, Carter S, Chopin LK, Herington AC (2010). 
"Ghrelin gene-related peptides: multifunctional endocrine / 
autocrine modulators in health and disease". 37 (1): 125–31.  
16) Holmes, G.L. Effect of non-sex hormones on neuronal 
excitability, seizures, and the electroencephalogram. 
Epilepsia. 1991; 32: S11–S18. 
17) Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng 
CH, Wise H. (2007) The truncated ghrelin receptor 
polypeptide (GHS-R1b) acts as a dominant-negative mutant 
of the ghrelin receptor. 
18) Taheri S, Lin L, Austin D, Young T, Mignot E (December 
2004). "Short Sleep Duration Is Associated with Reduced 
Leptin, Elevated Ghrelin, and Increased Body Mass Index". 
PLoS Med. 1 (3): e62.  
19) Diano S, Farr SA, Benoit SC, Horvath B, Gaskin FS, Nonaka 
N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin 
RSTschöp MH, Horvath TL (March 2006). "Ghrelin controls 
hippocampal spine synapse density and memory 
performance". Nat. 9 (3): 381–8. 55.  
20) Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, 
Witherington J, Pemberton DJ (2009)"Cognitive enhancing 
effects of ghrelin receptor agonists (3): 415–27.  
21) Spencer SJ, Xu L, Clarke MA, Lemus M, Reichenbach A, 
Geenen B, Kozicz T, Andrews ZB (September 2012). 
"Ghrelin regulates the hypothalamic-pituitary-adrenal axis 
and restricts anxiety after acute stress". Biol. Psychiatry 72 
(6): 457–65 
22) Waseem T, Duxbury M, Ito H, Rocha F, E, Ashley SW, 
Robinson MK (September 2004). "Ghrelin ameliorates TNF-a 
induced anti-proliferative and pro-apoptotic effects and 
promotes intestinal epithelial restitution". Journal of the 
American College of Surgeons 199 (3 Supplement): 16..  
23) Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK 
(March 2008). "Exogenous ghrelin modulates release of pro- 
and anti-inflammatory cytokines in LPS-stimulated 
macrophages through distinct signaling pathways". Surgery 
143 (3): 334–42.  
24) Gonzalez-Rey E, Chorny A, Delgado M (May 2006). 
"Therapeutic action of ghrelin in a mouse model of colitis". 
Gastroenterology 130 (6): 1707–20. doi:10.1053/ j.gastro. 
2006. 01.041. PMID 16697735.  
25) Wu R, Dong W, Ji Y, Zhou M, Marini CP, Ravikumar TS, 
Wang P (2008). "Orexigenic Hormone Ghrelin Attenuates 
Local and Remote Organ Injury after Intestinal Ischemia-
Reperfusion". PLoS ONE 3 (4): e2026. Bibcode: 2008PLoSO 
3.2026W.  
26) Işeri SO, Sener G, Yüksel M, Contuk G, Cetinel S, Gedik N, 
Yegen BC (December 2005). "Ghrelin against alendronate-
induced gastric damage in rats.187 (3): 399–406.  
27) Heppner KM, Tong J (2014). "Regulation of glucose 
metabolism by the ghrelin system: multiple players and 
multiple actions". 171 (1): R21–32. 
28) Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, 
Dellinger EP, Purnell JQ (May 2002). "Plasma ghrelin levels 
after diet-induced weight loss or gastric bypass surgery". N. 
Engl. J. Med. 346 (21): 1623–30.  
29) Santos M, MJ, Nogueira-Silva C, Melo-Rocha G, Henriques-
Coelho T, Roncon-Albuquerque R Jr, Leite-Moreira AF, De 
Krijger RR, Tibboel D, Rottier R, Correia-Pinto J 
(2006)."Ghrelin expression in human and rat fetal lungs and 
the effect of ghrelin administration in nitrofen-induced 
congenital diaphragmatic hernia".59 (4 Pt 1): 531–7.  
30) Yokota I, Kitamura S, Hosoda H, Kotani Y, Kangawa K 
(2005). Concentration of the n-octanoylated active form of 
ghrelin in fetal and neonatal circulation J. 52 (2): 271–6. 44. 
Yin Y, Li Y, 
31) Berilgen, M.S., Mungen, B., Ustundag, B., and Demir, C. 
Serum ghrelin levels are enhanced in patients with epilepsy. 
Seizure. 2006; 15: 106–111. 
32) Gower et al .1985. 
33) Shouse et al.,Basic mechanism underlying seiure prone and 
seizure resistant sleep.1990. 
34) Carskadon MAet al.,Normal human sleep overview.2000. 
35) Scheffer IE et al.,Autosomal dominant nocturnal frontal lobe 
epilepsy.1995. 
36) Beth A Malow ,Fromes GA, Aldrich MS.Usefulness of 
polysomnography in epilepsy patients.1997. 
37) Rechtschaffen A, Kales A.A manual of standardized 
terminology techniques and scoring system of sleep 
stages.1968. 
38) Dag, E., Aydin, S., Ozkan, Y., Erman, F., Dagli, A.F., and 
Gurger, M. Alteration in chromogranin A, obestatin and total 
ghrelin levels of saliva and serum in epilepsy cases. Peptides. 
2010; 31: 932–937 
39) Gungor, S., Yücel, G., Akinci, A., Tabel, Y., Ozerol, I.H., 
and Yologlu, S. The role of ghrelin in weight gain and growth 
in epileptic children using valproate. Child Neurol. 2007; 22: 
1384–1388 
40) Tomoum, H.Y. and El-Hadidi, E.S. Ghrelin and resistin levels 
in children with epilepsy on valproic acid. Pediatr Neurol. 
2009; 7: 223–229 
41) Shimada, M., Date, Y., Mondal, M.S., Toshinai, K., 
Shimbara, T., Fukunaga, K. et al. Somatostatin suppresses 
ghrelin secretion from the rat stomach. Biochem Biophys Res 
Commun. 2003; 302: 520–525 
42) Vezzani, A. and Hoye, D. Brain somatostatin: a candidate 
inhibitory role in seizures and epileptogenesis. Eur J 
Neurosci. 1999; 11: 3767–3776 
43) Gahete, M.D., Córdoba-Chacón, J., Salvatori, R., Castaño, 
J.P., Kineman, R.D., and Luque, R.M. Metabolic regulation 
of ghrelin O-acyl transferase (GOAT) expression in the 
mouse hypothalamus, pituitary, and stomach. Mol Cell 
Endocrinol. 2010; 317: 154–160. 
44) Bhatt, R., Bhatt, S., Rameshwar, P., and Siegel, A. Long-term 
kindled seizures induce alterations in hematopoietic 
functions: role of serum leptin. Epilepsy Res. 2005; 65: 169–
178 
45) Hum, K.M., Megna, S., and Burnham, W.M. Lack of 
laterality in the effects of right and left amygdala kindling on 
weight gain in female rats. Epilepsy Res. 2009; 87: 40–46 
46) Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., 
Ueno, N. et al. Ghrelin is an appetite-stimulatory signal from 
stomach with structural resemblance to motilin. 
Gastroenterology. 2001; 120: 337–345 
47) Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., 
and Oikawa, S. Effects of insulin, leptin, and glucagon on 
ghrelin secretion from isolated perfused rat stomach. Regul 
Pept. 2004; 119: 77–81 
48) Pan, W., Tu, H., and Kastin, A.J. Differential BBB 
interactions of three ingestive peptides: obestatin, ghrelin, 
and adiponectin. Peptides. 2006; 27: 911–916 
49) De Vriese, C., Gregoire, F., Lema-Kisoka, R., Waelbroeck, 
M., Robberecht, P., and Delporte, C. Ghrelin degradation by 
serum and tissue homogenates: identification of the cleavage 
sites. Endocrinology. 2004; 145: 4997–5005 
50) M.Said Berilgen et al 2005.Serum ghrelin levels are enhanced 
in patients with epilepsy. 
51) Weikel JC .Ghrelin promotes slow wave sleep. 
52) Shouse, M.N. Mechanisms of sleep and arousal: relationship 
to epilepsy. in: C.W. Bazil, B.A. Malow, M.R. Sammaritano 
(Eds.) Sleep and epilepsy: the clinical spectrum. Elsevier 
B.V., The Netherlands; 2002: 93 
53) Vaughn, B.V. and D’Cruz, O.F. Sleep and epilepsy. Semin 
Neurol. 2004; 24: 301–313 
54) Falconer, M.A., Serafetinides, E.A., and Corsellis, J.A. 
Etiology and pathogenesis of temporal lobe epilepsy. Arch 
Neurol. 1964; 10: 233–248 
55) Herzog, A.G. A hypothesis to integrate partial seizures of 
temporal lobe origin and reproductive endocrine disorders. 
Epilepsy Res. 1989; 3: 151–159 
56) Bilo, L., Meo, R., Valentino, R., Buscaino, G.A., Striano, S., 
and Nappi, C. Abnormal pattern of luteinizing hormone 
pulsatility in women with epilepsy. Fertil Steril. 1991; 55: 
705–711 
57) Zobel, A., Wellmer, J., Schulze-Rauschenbach, S., Pfeiffer, U., 
Schnell, S., Elger, C. et al. Impairment of inhibitory control of 
the hypothalamic pituitary adrenocortical system in epilepsy. 
Eur Arch Psychiatry Clin Neurosci. 2004; 254: 303–311. 
58) Sakata I, Sakai T (2010). Ghrelin cells in the gastrointestinal  
tract" . 
59) Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, 
Meguid MM, Fujimiya M ."Ghrelin, appetite, and gastric 
motility: the emerging role of the stomach as an endocrine 
organ"2004. 
60) Dickson SL, Egecioglu E, Landgren S, (2011) "The role of 
the central ghrelin system in reward from food and chemical 
drugs"l. 340 (1): 80–87. 
61) Perello M, Scott MM, Sakata I, Lee CE, Chuang JC, Osborne-
Lawrence S, (2012)."Functional implications of limited leptin 
receptor and ghrelin receptor co expression in the brain".. 520 
(2): 281–94.  
62) Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, 
Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami 
G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, 
Kangawa K, Nakao K (October 2001). "Stomach is a major 
source of circulating ghrelin, and feeding state determines 
plasma ghrelin-like immunoreactivity levels in humans". J. 
Clin. Endocrinol. Metab. 86 (10): 4753–8..  
63) Suckale .Pancreas islets in metabolic signalling 
64) Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB 
(2004). "Ghrelin—a hormone with multiple functions". Front 
Neuroendocrinol. 25 (1): 27–68.  
65) Baldy-Moulinier M. Sleep architecture and childhood absence 
epilepsy. Epilepsy Res Suppl 1992;6: 195–8. 
66) Besset A. Influence of generalized seizures on sleep 
organization. In: StermanMB, ShouseMN, PassouantP, eds. 
Sleep and epilepsy. Academic Press, 1982: 347–60. 
67) Baldy-Moulinier M. Temporal lobe epilepsy and sleep 
organization. In: StermanMB, ShouseMN, PassouantP, eds. 
Sleep and epilepsy. Academic Press, 1982: 339–46. 
68) Bazil CW, Castro LH, Walczak TS. Reduction of rapid eye 
movement sleep by diurnal and nocturnal seizures in temporal 
lobe epilepsy. Arch Neurol 2000;  57: 363–8. 
69) Crespel A, Baldy-Moulinier M, Coubes P. The relationship 
between sleep and epilepsy in frontal and temporal lobe 
epilepsies: practical and physiopathologic considerations. 
Epilepsia 1998;39: 150– 
70) Zucconi M, Oldani A, Smirne S, et al. The macrostructure 
and microstructure of sleep in patients with autosomal 
dominant nocturnal frontal lobe epilepsy. J Clin Neurophysiol 
2000;17: 77–86. 
71) Cortesi F, Giannotti F, Ottaviano S. Sleep problems and 
daytime behavior in childhood idiopathic epilepsy. Epilepsia 
1999;40: 1557–65. 
72) Dahl RE, Pelham WB, Wierson MC. The role of sleep 
disturbance in attention deficit disorder symptomatology: a 
case study. J Pediatr Psychol 1991;16: 229–39. 
73) Placidi F, Scalsie A, Marciani MG, et al. Effect of 
antiepileptic drugs on sleep. Clin Neurophysiol 
2000;111(suppl 2):S115–9. 
74) Sammaritano M, Sherwin A. Effect of anticonvulsants on 
sleep. Neurology 2000;54(supp1):S16–24.  
75) Wolf P. Influence of antiepileptic drugs on sleep. In: WolfP, 
DamJ, JanzD, et al., eds. Advances in epileptology. New 
York : Raven Press, 1987: 733–7.  
 
76) Legros B, Bazil CW. Effects of antiepileptic drugs on sleep 
architecture: a pilot study. Sleep Med 2003;4: 51–5. 
77) Palm L, Anderson H, Elmquist D, et al. Daytime sleep 
tendency before and after discontinuation of antiepileptic 
drugs in preadolescent children with epilepsy. Epilepsia 
1992;33: 687–91. 
78) Blaise B. The relationship between sleep and epilepsy in 
children. Semin Pediatr Neurol 1996;3: 29–35.  
79) Holmes, E., Davies, I. Circulating ghrelin exists in both 
lipoprotein bound and free form. 
80) Wren, A.M Ghrelin causes hyperphagia and obesity in 
rats.2001 
81) Feighner ,S. D ,Howard AD. Structural requirements for 
activation the human GHSR by peptide secretagogues. 
82) Kirchner, H  GOAT links dietary lipids with the endocrine 
control of energy balance. 2009 
83) Gomez et al. ghrelin and GOAT co expressed in chondrocytes, 2009. 
84) Barnett BP. Glucose and weight control in mice with GOAT 
inhibitor. 
85) Barzon L et al Loss of GHSR 1a and over expression of type 
1 b.2005. 
86) Zhang W (2014). The growth hormone secretagogue  
receptor; its signalling and regulation. 4837-55.  
 
INFORMED CONSENT FORM 
Title of the study: “A study of Polysomnography and serum 
Ghrelin levels in patients with generalized 
tonic-clonic seizures”.   
Name of the Participant:  
Name of the Principal Investigator: Dr. K. Meenakumari 
Name of the Institution:  
Institute of Physiology and Experimental Medicine, 
 Madras Medical College and Govt. General Hospital, 
 Chennai - 3 
Documentation of the informed consent 
I _____________________________ have read the 
information in this form (or it has been read to me). I was free to 
ask any questions and they have been answered. I am over 18 years 
of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in 
“A study of Polysomnography and serum Ghrelin levels in 
patients with Generalized tonic clonic seizures. 
1) I have read and understood this consent form and the 
information provided to me. 
2) I have had the consent document explained to me. 
3) I have been explained about the nature of the study. 
4) I have been explained about my rights and responsibilities by 
the investigator. 
5) I have been informed the investigator of all the treatments I 
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6) I have been advised about the risks associated with my 
participation in this study. 
7) I agree to cooperate with the investigator and I will inform 
him/her immediately if I suffer unusual symptoms.  
8) I have not participated in any research study within the past 
_________month(s).  
9) I am aware of the fact that I can opt out of the study at any 
time without having to give any reason and this will not 
affect my future treatment in this hospital.  
10) I am also aware that the investigator may terminate my 
participation in the study at any time, for any reason, without 
my consent.  
11) I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this 
study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC. I understand that they are publicly presented. 
12) I have understood that my identity will be kept confidential if 
my data are publicly presented. 
13) I have had my questions answered to my satisfaction. 
14) I have decided to be in the research study. 
I am aware that if I have any question during this study, I 
should contact the investigator. By signing this consent form I 
attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of 
this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or 
legal representative if participant incompetent) 
Name _________________________ 
Signature_________________  Date________________ 
Name and Signature of impartial witness (required for illiterate 
patients): 
Name _________________________ 
Signature_________________  
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative 
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Name _________________________ 
Signature_________________  
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PROFORMA 
1) Name : 
2) Age: 
3) Sex: 
4) Address : 
5) Occupation : 
6) Complaints/duration: 
7)  History of present illness: 
8) History of any sleep disturbance after the onset of epilepsy? 
9) Past history: 
10) History of any drug intake 
11) History of associated illness: 
a. Diabetes 
b. Hypertension 
c. Ischemic heart disease 
d. Respiratory diseases 
e. Renal diseases 
INVESTIGATIONS : 
  Fasting  serum Ghrelin level 
Polysomnography 
EXAMINATION: 
General examination: 
    Temperature: 
     Pulse rate 
     Blood pressure:  
Systemic examination: 
    Cardiovascular system: 
    Respiratory system: 
    Gastrointestinal system: 
    Central nervous system: 
 



Master Chart - Control group
S NO: SS -I SS -II SS -III SS -IV REM Non- REM SS -I SS -II SS -III SS -IV Rapid Eye Mov.N n- REM NAP time NAP statusNAP onset latencyghrelin pg/mi PSQI ESS
1 8 125 40 45.5 50.5 218.5 2.97% 46.47% 14.87% 16.91% 18.77% 81.23% 269 91.5 5 169 0 13
2 17 201 40 65.5 75 323.5 4.27% 50.44% 10.04% 16.44% 18.82% 81.18% 398.5 92.25 12.5 98 0 3
3 17 220 60.5 80 53 377.5 3.95% 51.10% 14.05% 18.58% 12.31% 87.69% 430.5 89.97 14 89 1 7
4 11 180 45 52 62 288 3.14% 51.43% 12.86% 14.86% 17.71% 82.29% 350 75.57 18 78 1 4
5 17 179 35 35 67 266 5.11% 53.75% 10.51% 10.51% 20.12% 79.88% 333 88.03 20.5 178 5 8
6 13.5 181.5 45 43 91 283 3.61% 48.53% 12.03% 11.50% 24.33% 75.67% 374 92.52 7.5 56 5 7
7 18 165 44 9 85 283 4.89% 44.84% 11.96% 15.22% 23.10% 76.90% 368 89.64 14 79.8 0 6
8 12.5 176.5 46 50 93.5 285 3.30% 46.63% 12.15% 13.21% 24.70% 75.30% 378.5 90.39 6 120 0 6
9 15.5 178.5 43.5 55 84.5 292.5 4.11% 47.35% 11.54% 14.59% 22.41% 77.59% 377 95.8 14 110.5 0 8
10 15 189.5 44.5 34.5 68.5 283.5 4.26% 53.84% 12.64% 9.80% 19.46% 80.54% 352 95.67 12 124.5 0 8
11 16.5 215.5 54 45 63 331 4.19% 54.70% 13.71% 11.42% 15.99% 84.01% 394 94.08 6.5 100.6 2 8
12 10.5 223.5 42 32.5 65.5 308.5 2.81% 59.76% 11.23% 8.69% 17.51% 82.49% 374 90.12 8.5 98.6 0 7
13 12 213 40 40 65.5 305 3.24% 57.49% 10.80% 10.80% 17.68% 82.32% 370.5 91.12 18 157 2 4
14 11.5 202 36 39 70.5 288.5 3.20% 56.27% 10.03% 10.86% 19.64% 80.36% 359 93.24 28 90.9 0 6
15 15.5 198.5 31 45 102 290 3.95% 50.64% 7.91% 11.48% 26.02% 73.98% 392 91.65 24 120.3 2 4
16 16 201 38 43 83.5 298 4.19% 52.69% 9.96% 11.27% 21.89% 78.11% 381.5 93.45 15 111 0 5
17 16.5 172 43 39 91 270.5 4.56% 47.58% 11.89% 10.79% 25.17% 74.83% 361.5 94.63 19 99 0 3
18 12.5 203 28 34 87 277.5 3.43% 55.69% 7.68% 9.33% 23.87% 76.13% 364.5 91.35 9.5 145 0 4
19 17 182 48 45 91 292 4.44% 47.52% 12.53% 11.75% 23.76% 76.24% 383 91.72 6 174.5 0 9
20 14.5 216.5 38 26 90.5 295 3.76% 56.16% 9.86% 6.74% 23.48% 76.52% 385.5 95.66 10 90.7 0 6
21 17.5 202 31 43 70.5 293.5 4.81% 55.49% 8.52% 11.81% 19.37% 80.63% 364 90.32 16.5 123 0 4
22 16.5 219 35 39 58 309.5 4.49% 59.59% 9.52% 10.61% 15.78% 84.22% 367.5 92.79 12 167 1 8
23 12.5 212 36 32 75 292.5 3.40% 57.69% 9.80% 8.71% 20.41% 79.59% 367.5 93.75 18 90.5 0 5
24 17 210 33 41 68 301 4.61% 56.91% 8.94% 11.11% 18.43% 81.57% 369 95.84 22 143 1 8
25 16 232 38 48 75 334 3.91% 56.72% 9.29% 11.74% 18.34% 81.66% 409 88.53 24.5 104.9 0 6
26 14.5 199 49 40 82 302.5 3.77% 51.76% 12.74% 10.40% 21.33% 78.67% 384.5 90.6 17 120 0 4
27 12.5 224 45 42.5 91.5 324 3.01% 53.91% 10.83% 10.23% 22.02% 77.98% 415.5 92.61 13.5 110 0 6
28 11 218 34 49 86.5 312 2.76% 54.71% 8.53% 12.30% 21.71% 78.29% 398.5 89.55 17 110.5 1 4
29 16.5 200 36 35.5 90 288 4.37% 52.91% 9.52% 9.39% 23.81% 76.19% 378 94.1 10.5 99 1 9
30 17 185 49 40 82 291 4.56% 49.60% 13.14% 10.72% 21.98% 78.02% 373 91.09 12 90 1 7
Master Chart - GTCS group
S NO: SS -I SS -II SS -III SS -IV REM Non- REM SS -I SS -II SS -III SS -IV Rapid Eye Mov.N n- REM NAP time NAP statusNAP onset latencyghrelin pg/ml PSQI ESS
1 15.5 200 15 35.5 45 266 4.98% 64.31% 4.82% 11.41% 14.47% 85.53% 311 68 5 56.4 1 2
2 15.5 167.5 20.5 46 42.5 249.5 5.31%b                                7.02% 15.75% 14.55% 85.45% 292 80.66 12.5 46.8 3 5
3 15.5 185.5 45 40 43 286 4.71% 56.38% 13.68% 12.16% 13.07% 86.93% 329 90.07 14 67.5 7 11
4 19.5 198 38 49 52 304.5 5.47% 55.54% 10.66% 13.74% 14.59% 85.41% 356.5 74.57 18 70.6 3 13
5 19.5 224 28.5 33 50.5 305 5.49% 63.01% 8.02% 9.28% 14.21% 85.79% 355.5 91.28 22 67 4 1
6 15.5 205 37 40 81 297.5 4.10% 54.16% 9.78% 10.57% 21.40% 78.60% 378.5 89.2 7.5 88 6 1
7 21 197 41 54 50 313 5.79% 54.27% 11.29% 14.88% 13.77% 86.23% 363 86.95 14 65.9 2 11
8 14.5 202.5 43 42 77.5 302 3.82% 53.36% 11.33% 11.07% 20.42% 79.58% 379.5 82.41 12 55 4 4
9 17.5 200.5 44.5 44 44 306.5 4.99% 57.20% 12.70% 12.55% 12.55% 87.45% 350.5 89.5 14 66.9 4 12
10 16.5 185.5 40 45.5 55 287.5 4.82% 54.16% 11.68% 13.28% 16.06% 83.94% 342.5 92.13 7 87 7 6
11 17 220 29 46.5 60.5 312.5 4.56% 58.98% 7.77% 12.47% 16.22% 83.78% 373 90.03 9.5 76.9 4 10
12 20.5 208.5 39 40.5 75 308.5 5.35% 54.37% 10.17% 10.56% 19.56% 80.44% 383.5 86.07 8.5 77 2 12
13 17.5 220 45 46 52.5 328.5 4.59% 57.74% 11.81% 12.07% 13.78% 86.22% 381 86.79 20 39.7 3 10
14 13.5 200.5 39.5 47.5 60.5 301 3.73% 55.46% 10.93% 13.14% 16.74% 83.26% 361.5 90.07 28 50.6 13 9
15 17.5 220.5 40 46.5 88 324.5 4.24% 53.45% 9.70% 11.27% 21.33% 78.67% 412.5 89.01 24 54.6 4 12
16 19.5 230.5 38.5 40 62.5 328.5 4.99% 58.95% 9.85% 10.23% 15.98% 84.02% 391 85.5 19.5 76 3 11
17 20 200.5 40.5 45.5 82 306.5 5.15% 51.61% 10.42% 11.71% 21.11% 78.89% 388.5 89.67 19 80 2 11
18 25 236.5 25.5 44 76 331 6.14% 58.11% 6.27% 10.81% 18.67% 81.33% 407 80.57 9.5 49.6 8 9
19 20 212.5 45 57 60 334.5 5.07% 53.87% 11.41% 14.45% 15.21% 84.79% 394.5 75.61 10 50.4 6 9
20 18.5 219.5 35 3.55 79.5 276.55 5.20% 61.65% 9.83% 1.00% 22.33% 77.67% 356.05 67.63 18 90 3 15
21 20.5 214.5 33.5 40 55.5 308.5 5.63% 58.93% 9.20% 10.99% 15.25% 84.75% 364 86.75 16.5 78.8 1 11
22 19.5 223 38.5 46.5 60 327.5 5.03% 57.55% 9.94% 12.00% 15.48% 84.52% 387.5 87.79 12 56 4 10
23 24 235.5 33.5 30 64 323 6.20% 60.85% 8.66% 7.75% 16.54% 83.46% 387 84.66 18 70 4 7
24 16.5 214 45.5 48.5 66 324.5 4.23% 54.80% 11.65% 12.42% 16.90% 83.10% 390.5 88.86 22 49 2 10
25 21.5 235 35.5 45 64 337 5.36% 58.60% 8.85% 11.22% 15.96% 84.04% 401 79.88 26 76.5 8 12
26 17.5 222 45 46.5 67.5 331 4.39% 55.71% 11.29% 11.67% 16.94% 83.06% 398.5 67.99 20 47.6 3 12
27 17.5 226.5 35 38.5 70 317.5 4.52% 58.45% 9.03% 9.94% 18.06% 81.94% 387.5 85.86 15.5 89 4 13
28 14.5 222 40 45.5 75.5 322 3.65% 55.85% 10.06% 11.45% 18.99% 81.01% 397.5 92.19 21 60 2 7
29 17 220.5 32.5 45 79 315 4.31% 55.96% 8.25% 11.42% 20.05% 79.95% 394 88.84 10.5 46.8 2 2
30 22.5 200.5 41 48 79.5 312 5.75% 51.21% 10.47% 12.26% 20.31% 79.69% 391.5 89 12 98 1 2
